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A B S T R A C T
Background
Sexual dysfunction (including altered sexual desire, orgasmic and ejaculatory dysfunction, erectile and other problems) is a relatively
common side effect of antidepressant medication. These sexual side effects may compromise a person’s lifestyle and result in a lack of
compliance with the prescribed antidepressant to the detriment of the person’s mental health. A wide range of management strategies
are possible to address this problem, including behavioural, psychological and pharmacological approaches.
Objectives
1. To determine the effectiveness of management strategies for sexual dysfunction caused by antidepressants.
2. To determine the adverse effects and acceptability of the different management strategies.
Search methods
We searched the Cochrane Depression, Anxiety and Neurosis Group’s Specialized Register (CCDANCTR, to 1 January 2013), which
includes relevant randomised controlled trials from the following bibliographic databases: The Cochrane Library (all years), EMBASE
(1974 to date), MEDLINE (1950 to date) and PsycINFO (1967 to date). Additional searches were carried out by the author team on
the same biomedical databases (using terms for ’sexual dysfunction’ only) together with CINAHL (1982 to Jan 2012). The reference
lists of reports of all included studies were screened.
Selection criteria
We included randomised controlled trials that compared management strategies for antidepressant-induced sexual dysfunction versus
placebo or any alternative strategy.
Data collection and analysis
Two authors independently extracted data and assessed trial quality. Study authors were contacted for additional information.
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Main results
We included 23 trials involving 1886 people in this updated review. Twenty-two of these trials investigated the addition of medication
to treat the identified dysfunction, with most agents studied in only single studies. One study investigated switching to an alternative
antidepressant.
In men, data for the phosphodiesterase inhibitors sildenafil (three studies, 255 participants) and tadalafil (one study, 54 participants)
indicated they led to a greater improvement in erectile function than placebo. Combined data from three sildenafil studies found benefit
over placebo on International Index of Erectile Function ratings of ability to achieve (MD 1.04, 95% CI 0.65 to 1.44), and maintain
erections (MD 1.18, 95% CI 0.78 to 1.59). A single point improvement on these ratings is equivalent to an improvement in frequency
from ’sometimes’ to ’most times’. Men receiving tadalafil were more likely to report improved erectile function (RR 11.50, 95% CI
3.03 to 43.67). For women it remains uncertain whether sildenafil is more effective than placebo. Unpublished data could reduce this
uncertainty.
Data from three studies in men and women of bupropion 150 mg twice daily indicate a benefit over placebo on rating scale scores
(SMD 1.60, 95% CI 1.40 to 1.81), but response rates in two studies of bupropion 150 mg once daily demonstrated no statistically
significant difference in effect (RR 0.62, 95% CI 0.09 to 4.41).
Other augmentation strategies failed to demonstrate significant improvements in sexual dysfunction compared with placebo.
One trial involving 75 people with sexual dysfunction due to sertraline assessed the effect of changing antidepressant. Switching to
nefazodone was significantly less likely to result in the re-emergence of sexual dysfunction than restarting sertraline (RR 0.34, 95% CI
0.19 to 0.60), however, nefazodone is no longer available for clinical use.
There is an absence of randomised trials assessing the effects of switching to currently-available antidepressant agents with lower rates
of adverse sexual effects, the role of psychological or mechanical interventions, or of techniques such as drug holidays.
We identified no data for any of the strategies included in the trials assessed that indicated that they led to a worsening of psychiatric
symptoms. However, the relatively small numbers assessed for many of the interventions studied means that the possibility of such an
effect cannot confidently be excluded in all cases.
Given the small numbers of studies assessing most of the strategies assessed, the presence of any unpublished trials could have substantial
effects on estimates of effect. In some cases, only results from particular items or subscales within ratings scales are available. It is likely
that this could act to bias estimates of effect obtained, increasing apparent effectiveness.
Authors’ conclusions
The evidence currently available is rather limited. For men with antidepressant-induced erectile dysfunction, the addition of sildenafil
or tadalafil appears to be an effective strategy. For women with antidepressant-induced sexual dysfunction the addition of bupropion
at higher doses appears to be the most promising approach studied so far.
P L A I N L A N G U A G E S U M M A R Y
Strategies for managing sexual dysfunction caused by antidepressants
Antidepressants can have numerous effects on sexual function including altered sexual desire, erection difficulties and orgasm problems.
This systematic review investigated different ways to manage such sexual dysfunction. We included 23 randomised studies, with a
total of 1886 participants who had developed their sexual problems while taking antidepressant medication. Twenty-two of these
studies looked at the addition of further medication to the ongoing treatment for depression. For men with antidepressant-induced
erectile dysfunction, the addition of sildenafil (Viagra; three studies, 255 participants) or tadalafil (Cialis; one study, 54 participants)
appeared to improve the situation. For women with antidepressant-induced sexual dysfunction the addition of bupropion (Wellbutrin,
Zyban; three studies, 482 participants) at higher doses appears to be the most promising approach studied so far, but further data from
randomised trials are likely to be required before it can be recommended confidently. We did not find evidence that any intervention
led to a worsening of psychiatric symptoms; however, we cannot be confident of this for many of the interventions studied, as only
small numbers of participants have been studied so far.
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B A C K G R O U N D
Description of the condition
Antidepressant medications are widely prescribed (Donoghue
1996; Jick 1995; Moore 2009). Sexual dysfunction is a com-
mon, well-known adverse effect of all antidepressants (Balon 1993;
Baldwin 1997; Williams 2006; Williams 2010). These sexual ad-
verse effects can affect a person’s lifestyle considerably, and, where
this results in reduced compliance with medication, lead to less
effective treatment of the primary psychiatric disorder.
Several different types of sexual dysfunction may be related to an-
tidepressants, including altered sexual desire - such as loss or lack
of desire; orgasmic and ejaculatory dysfunction, including anor-
gasmia (inability to achieve orgasm), hyperorgasmia (significantly
more orgasms in a short time period than normal), painful orgasm
and inhibited ejaculation; erectile problems, including erectile dys-
function (impotence), priapism (significantly prolonged erection)
and painful erection - and other issues, including problems of sex-
ual arousal, reduced sexual satisfaction, lubrication, dyspareunia
(painful intercourse) and vaginismus (tensing of vaginal muscles
that make intercourse painful or impossible).
Identifying antidepressant-induced sexual dysfunction can be
complicated by the association of sexual dysfunction with some
disorders that antidepressants are used to treat. For example, de-
pression is associated with increased rates of reported sexual dys-
function even when no treatment is received (Angst 1998).
Sexual dysfunction has been reportedwith all classes of antidepres-
sant medication. Reported rates of sexual dysfunction are typically
underestimates, as sexual adverse effects are often not specifically
asked about in treatment trials, while direct questioning can reveal
higher rates than are reported spontaneously (Montejo-Gonzalez
1997). Studies of the prevalence of antidepressant-induced sexual
dysfunction have exhibited a number of methodological problems
(Montgomery 2002). These include the frequent absence of com-
parison groups or baseline assessments, and inconsistent defini-
tions of sexual dysfunction between studies.
Themajority of studies directly comparing rates of sexual dysfunc-
tion between different antidepressants have involved selective sero-
tonin reuptake inhibitors (SSRIs). Generally, trials have reported
no significant differences between these drugs in rates of sexual dys-
function, with sexual dysfunction reported in population surveys
by over one third of participants (Williams 2006;Williams 2010).
In randomised trials, nefazodone (a serotonin antagonist and re-
uptake inhibitor) and bupropion (a norepinephrine-dopamine re-
uptake inhibitor) have been associated with less sexual dysfunction
than the SSRI, sertraline (Croft1999; Feiger 1996), and reboxetine
(a norepinephrine reuptake inhibitor) with greater sexual satisfac-
tion than the SSRI fluoxetine (Clayton 2003). The monoamine
oxidase inhibitor, moclobemide, was more commonly associated
with increased sexual desire than the tricyclic antidepressant, dox-
epin (Philipp 1993). Further information on rates of sexual dys-
function with antidepressants can be found elsewhere (Gregorian
2002; Montgomery 2002; Serretti 2009).
Description of the intervention
Management strategies described for the treatment of antidepres-
sant-induced sexual dysfunction include waiting for the problem
to resolve; behavioural strategies modifying sexual technique; in-
dividual and couple psychotherapy; alterations of antidepressant
usage, including reducing dose; delaying use until after sexual ac-
tivity; ’drug holidays’; switching to a different antidepressant; and
the use of additional agents (Baldwin 2004). A wide range of
additional agents have been employed clinically to try to reverse
this problem, for example erectile dysfunction might be treated
with a phosphodiesterase inhibitor such as sildenafil or tadalafil.
However, additional treatments may themselves have adverse ef-
fects and tolerability problems, and could, in theory, affect the
primary psychiatric condition for which the antidepressants were
prescribed.
How the intervention might work
The mechanisms by which antidepressants cause sexual dysfunc-
tion involve complex multi-system interactions, which are not en-
tirely understood. Psychological factors such as anxiety may also
play a role in maintaining dysfunction. The main neurotransmit-
ters involved are serotonin (5HT), acetylcholine, noradrenaline,
and dopamine. The adverse sexual effects may be caused centrally
or peripherally and may result from the change in function of one
or more neurotransmitter. Given this complex system, additional
treatments employed have had a wide variety of putative mech-
anisms. Such treatments have included sildenafil (a phosphodi-
esterase inhibitor), amantadine (a dopamine agonist), cyprohepta-
dine (an antihistamine and 5HT blocker), yohimbine (an alpha-2
blocker), buspirone (a 5HT1A receptor agonist), bethanechol (an
acetylcholine agonist) and Ginkgo biloba (a herbal medication).
Why it is important to do this review
This is an update of a Cochrane review first published in 2004.
That review noted that the available evidence was rather limited,
with small numbers of trials assessing each strategy. This review
aims to summarise the current evidence regarding potential strate-
gies formanaging antidepressant-induced sexual dysfunction, not-
ing how well the sexual dysfunction responds, as well as risks,
such as adverse effects or worsening of the condition for which the
antidepressant was initially prescribed. This should assist patients
and their clinicians when deciding how best to manage these com-
mon problems.
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Attention is drawn to the related Cochrane review on the man-
agement of sexual dysfunction due to antipsychotic drug therapy
(Berner 2007; Schmidt 2012).
O B J E C T I V E S
1. To determine the effectiveness of management strategies for
sexual dysfunction caused by antidepressants.
2. To determine the adverse effects and acceptability of the differ-
ent management strategies.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials in the review. Cluster
randomised trials and trials of both parallel group and cross-over
design were considered suitable for inclusion.Trials using non-
randomised allocation were not included, in order to reduce risks
of selection and publication bias (Alderson 2004).
Types of participants
Patients aged 16 years and over with sexual dysfunction (includ-
ing, but not restricted to altered sexual desire, orgasmic and ejacu-
latory dysfunction, erectile problems, problems of sexual arousal,
reduced sexual satisfaction, lubrication, dyspareunia and vaginis-
mus).as a result of being treated with an antidepressant (except
mood stabilisers) on any dose regime.
Participants from inpatient or community settings were eligible
for inclusion.
Inclusion was not restricted on the basis of the disorder for which
the antidepressant had been prescribed.
Types of interventions
Experimental intervention
Anymanagement strategy - pharmacological, psychological or oth-
erwise - for antidepressant-induced sexual dysfunction.
Comparator intervention
Placebo or any alternative strategy.
Types of outcome measures
Primary outcomes
1. Changes, or post-treatment differences, in the severity of the
identified sexual dysfunction (assessed by self (self-ratedmeasures)
or interviewer (interviewer-rated measures), or both.
Secondary outcomes
2. Changes, or post-treatment differences, in sexual satisfaction
and functioning (based on self- or interviewer-rated measures, or
both).
3. Dropout rates as a measure of the acceptability of specific ther-
apies.
4. Change, or post-treatment differences, in the primary psychi-
atric condition for which the antidepressant was being prescribed
(based on symptom ratings).
Outcomes at trial endpoint were employed, where available. No
decision was made to favour self-reported or interviewer-rated
measures.
Search methods for identification of studies
CCDAN’s Specialized Register (CCDANCTR)
The Cochrane Depression, Anxiety and Neurosis Group (CC-
DAN) maintains two clinical trials registers at the editorial base
(Bristol, UK), a references register and a studies-based register. The
CCDANCTR-References Register contains over 29,500 reports
of randomised controlled trials in depression, anxiety and neurosis.
Approximately 65% of these references have been tagged to indi-
vidual, coded trials. The coded trials are held in theCCDANCTR-
Studies Register and records are linked between the two registers
through the use of unique Study ID tags. Coding of trials is based
on the EU-Psi coding manual. Please contact the CCDAN Trials
Search Co-ordinator for further details. Reports of trials for inclu-
sion in the Group’s registers are collated from routine (weekly),
generic searches of MEDLINE (1950 to date), EMBASE (1974
to date) and PsycINFO (1967 to date); quarterly searches of the
Cochrane Central Register of Controlled Trials (CENTRAL) and
review-specific searches of additional databases. Reports of trials
are also sourced from international trials registers c/o the World
Health Organization’s trials portal (ICTRP), drug companies, the
handsearching of key journals, conference proceedings and other
(non-Cochrane) systematic reviews and meta-analyses. Details of
CCDAN’s generic search strategies can be found on the Group’s
website.
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Electronic searches
Electronic searches included:
1. The CCDANCTR-Studies Register (all years to 1 August 2012,
with a further update search for 1 January 2013), using the fol-
lowing coding terms:
Condition = ( “sexual dysfunction*” and “drug induced”) or Co-
morbidity = (“sexual dysfunction*”).
2. The CCDANCTR-References Register, using a more sensitive
set of free-text terms to find additional untagged/uncoded refer-
ences (Appendix 1).
3. Independent searches by the author team on the Cochrane Reg-
ister of Controlled Trials (CENTRAL) (2012, Issue 1), CINAHL
(1982 to 12 January 2012), EMBASE (1980 to 12 January 2012),
MEDLINE (1966 to 12 January 2012) and PsycINFO (1984 to
12 January 2012) (Appendix 2).
4. International trials registries (ClinicalTrials.gov and ICTRP,
1 January 2013), to identify additional ongoing or unpublished
studies .
Searching other resources
Reference checking
The reference lists of all trials identified for inclusion were exam-
ined, together with other articles on adverse sexual effects of an-
tidepressants, and relevant conference proceedings.
Personal communications
The following experts in the field of sexology were contacted for
the original review: J Bancroft, R Basson, J Heiman and R Rosen.
Pharmaceutical companies
For the original review, the authors contacted pharmaceutical com-
paniesmanufacturing antidepressantmedication to findout if they
knew of any published or unpublished studies relevant to this re-
view. This search was not repeated for the update.
Data collection and analysis
Selection of studies
Trial inclusion or exclusion was determined independently by two
authors. Full reports of studieswere used for this assessment, except
where a trial could be excluded on the basis of title and abstract
alone. Any disagreements were resolved by consensus discussion
with a third member of the review team.
Data extraction and management
Data were extracted from the included studies about participants’
characteristics, intervention details (including whether or not the
study was of a discontinuation design) and outcome measures.
The data were extracted independently by two authors. Where
inadequate trial data were provided, the authors were contacted in
order to obtain further information. Where standard deviations
were not reported but could be calculated from standard errors this
was done in conventional fashion (Cochrane Handbook chapter
7.7.3.3 Higgins 2009). Any disagreements were resolved by con-
sensus discussion with a third member of the review team.
Main planned comparisons
We planned to compare each experimental intervention with
placebo or alternative comparator intervention, and, where pos-
sible, to group comparisons of interventions with similar mecha-
nisms.
Assessment of risk of bias in included studies
Two authors independently assessed the methodological quality
of the included studies using the Cochrane Collaboration tool for
risk of bias (Higgins 2011). Any disagreements were resolved by
consensus discussion with a third member of the review team.
The risk of bias tool assesses seven domains namely: sequence
generation, allocation concealment, blinding of participants and
personnel, blinding of outcome assessment, incomplete outcome
data, selective outcome reporting and ‘other issues’. Each domain
is assigned one of the following judgements: ‘low risk’ of bias, ‘high
risk’ of bias, or ‘unclear risk’ of bias, and a supporting statement
is provided to back up the judgement.
Measures of treatment effect
Data were analysed using Review Manager software (version 5.2).
For binary efficacy outcomes, a pooled risk ratio (with 95% con-
fidence intervals) was calculated using a fixed-effect model. Risk
ratios are reported since this measure can be more readily applied
in clinical practice (Sackett 1996; Sinclair 1994). For continuously
distributed outcomes, the mean difference (MD) was calculated
when the same scale was used by all studies. Standardised mean
difference was employed for comparisons across different scales.
We extracted outcome data collected from any time point, but our
reported analyses use trial endpoint data, except where specified.
Differences between trials in the times of assessment are reported.
Unit of analysis issues
Cluster-randomised trials
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The review protocol did not address how we would include data
from cluster-randomised trials. Although none have been encoun-
tered in this review, the appropriate methods, should they need to
be included, will be included in a future update of this review.
Cross-over trials
We intended to use data from the first period of treatment only
for cross-over trials, but we did use pooled data from both periods
where these were the only data available.
Studies with multiple treatment groups
Where studies includedmultiple treatment groups, pair-wise com-
parisons are reported. This may lead to increased correlation be-
tween estimated intervention effects across such comparisons, as
described in the Cochrane Handbook. Where possible, groups
were combined to create a single pair-wise comparison or alterna-
tively the ‘shared’ control group data were split into two or more
groups with smaller sample size(s).
Dealing with missing data
We used trial data from intention-to-treat analyses when available.
Where this was not possible, we used endpoint data for the par-
ticipants who completed the trial. Where necessary, we wrote to
study authors to request missing data.
Assessment of heterogeneity
Statistical heterogeneity between studies was assessed using the I2
statistic. The Cochrane Handbook suggests interpretation of an I
2 of 0% to 40% as being potentially unimportant heterogeneity,
30% to 60% as representing moderate heterogeneity, 50% to 90%
indicating substantial heterogeneity, and 75% to 100% indicating
considerable heterogeneity (Higgins 2003).
Assessment of reporting biases
We considered methods to look for evidence of small study bias,
but the number of trials identified for each comparison was too
limited for this to be appropriate. Should the number of trials
available increase in future updates of this review, the use of meth-
ods such as funnel plots and statistical tests to identify possible
publication bias will be considered.
Data synthesis
Fixed-effect analyses are presented unless otherwise stated. Ran-
dom-effects models were used routinely to investigate the sensitiv-
ity of results to the choice of statistical method, but we observed
no cases where this altered estimates of effect qualitatively.
Subgroup analysis and investigation of heterogeneity
Subgroup analyses were planned by:
1. Gender of those experiencing sexual dysfunction (men only,
women only, mixed group).
2. Dose of intervention.
Sensitivity analysis
Possible sensitivity analyses were considered to assess the impact
of differences in study methodology on outcomes, but no such
analyses were performed in view of the small numbers of trials
identified for each intervention.
’Summary of findings’ table
As this review addresses more than one major treatment com-
parison, separate ’Summary of findings’ tables were prepared for
interventions where data were available from three or more tri-
als. Outcome data were summarised separately by gender, where
possible. Assumed baseline risks were taken from median control
group risks across included studies. Quality of evidence used was
assessed using the specific evidence grading system developed by
the GRADE working group (GRADE working group 2004).
R E S U L T S
Description of studies
Results of the search
Over 6000 citations were identified by the search strategy of this
review (Figure 1). Of these, 70 citations appeared potentially rel-
evant and 23 were included, 22 of which provided data for quan-
titative analysis.
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Figure 1. Study flow diagram
Further information was provided by the authors of several studies
(Clayton 2004; Ferguson 2001; Ginsberg 2001; Jacobsen 1996;
Michelson 2002; Nurnberg 2003).
Included studies
Design
We identified 23 studies that met the inclusion criteria for this
review (see Characteristics of included studies). Some additional
studies were identified too late for inclusion in this version of the
review, and so are awaiting classification (see Characteristics of
studies awaiting classification). If suitable, they will be included
in a future update of the review.
Nineteen studies were of parallel-group design, and three used
a cross-over design (Bernik 2004; Meston 2004; Nelson 2001).
Length of included trials ranged from 14 days to 26 weeks. Where
trials described a period of randomised treatment followed by a
non-randomised period, we have reported only the period of ran-
domised treatment.
Sample sizes
Numbers of people randomised within individual studies varied
greatly from12participants (Bernik 2004; Jespersen2004), to 288
(Baldwin 2008). This update adds new data from several studies
with over 100 participants (Baldwin 2008; Fava 2006; Safarinejad
2010; Safarinejad 2011).
Setting
Participants were recruited to studies taking place in a range of
countries. The greatest number of studies took place in the USA
and Europe, but studies were identified from South Korea (Kang
2002), and South Africa (Jespersen 2004), with two large new
studies from Iran (Safarinejad 2010, Safarinejad 2011).
Participants
The total number of participants randomised in the 23 studies
was 1886.
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Participants in 12 of the studies had developed adverse sexual
effects from the use of a selective serotonin reuptake inhibitor
(SSRI). Two participants in one study had received nortriptyline,
a tricyclic antidepressant (Kang 2002). One study did not specify
the type of antidepressant involved (Jespersen 2004).
Seven studies included only women (Jespersen 2004; Meston
2004; Michelson 2000; Michelson 2002; Nurnberg 2002;
Nurnberg 2008; Safarinejad 2011), and four studies included only
men ( Fava 2006; Ginsberg 2001; Nurnberg 2003; Safarinejad
2010). One study did not describe the gender of those participat-
ing (Masand 2001), and the remaining studies recruited both men
and women.
The participants in studies had wholly, or partially, recovered from
the disorder for which antidepressants had been prescribed - most
commonly depression (see Characteristics of included studies).
Two studies reported inclusion of mood and anxiety disorders
(Ginsberg 2001; Kang 2002), and one study included partici-
pants treated for depression, bipolar disorder and obsessive com-
pulsive disorder (Jacobsen 1996). One study was restricted to peo-
ple treated for panic disorder (Bernik 2004).
While most studies did not restrict inclusion to particular types
of sexual dysfunction, one study employing sildenafil restricted
inclusion to antidepressant-induced erectile dysfunction (Fava
2006), and another investigating bethanecol limited inclusion to
ejaculatory delay or anorgasmia (Bernik 2004).
Interventions
The range of intervention types assessedwas limited and is outlined
below.
Addition of further medication
Themajority of studies assessed the addition of furthermedication
to ongoing antidepressant treatment using a placebo control. Two
studies had more than one active treatment arm in addition to the
placebo arm of the trial (Michelson 2000; Michelson 2002).
The interventions for which the greatest number of studies were
identified were bupropion and sildenafil.
Sildenafil, a phosphodiesterase inhibitor, was investigated in five
trials with a total of 503 participants (Fava 2006; Ginsberg 2001;
Nurnberg 2002; Nurnberg 2003; Nurnberg 2008). The range of
doses taken once daily varied between 25 mg and 100 mg in one
study (Fava 2006), and a dose between 50 mg and 100mg was
employed in the remaining four studies (Ginsberg 2001;Nurnberg
2002; Nurnberg 2003; Nurnberg 2008).
Bupropion, which is thought to act by dual noradrenaline and
dopamine reuptake inhibition (Stahl 2004), was investigated
in five trials with a total of 579 participants (Clayton 2004;
DeBattista 2005; Masand 2001; Safarinejad 2010; Safarinejad
2011). Bupropion (sustained release) was prescribed at a dose of
150 mg daily in two studies (DeBattista 2005;Masand 2001), and
at 150 mg twice daily in the remaining studies (Clayton 2004;
Safarinejad 2010; Safarinejad 2011).
A wide range of other agents were investigated in fewer studies
including:
1. A second phosphodiesterase inhibitor, tadalafil (in doses of
10 mg or 20 mg), tested in one study with 54 participants
(Evliyao lu 2011).
2. Two 5HT1A receptor agonists: VML-670, a 5-HT1A
receptor agonist (300 µg once daily) tested in a study with 288
participants (Baldwin 2008), and buspirone, another 5-HT1A
receptor agonist (30 mg daily), tested in a study with 61
participants (Michelson 2000); the Michelson 2000 study also
included an active treatment as the comparison treatment,
amantadine, a dopaminergic agent (50 mg twice daily).
3. A herbal extract of Ginkgo biloba: two studies with 61
participants tested a herbal extract of Ginkgo biloba (240 mg
daily) (Kang 2002; Wheatley 2004).
4. Granisetron, a 5-HT3 antagonist, was investigated in two
studies with 32 participants (Jespersen 2004; Nelson 2001).
Nelson 2001 used a dose of 1 mg to 2 mg, but the dosage was
not specified in the other study.
5. Bethanecol (20 mg), an agent with mixed cholinergic and
adrenergic effects, investigated in one study with 12 participants
(Bernik 2004).
6. Two 5HT2 receptor antagonists, olanzapine (2.5 mg daily)
and mirtazapine (15 mg daily) were investigated in the same
four-arm study (Michelson 2002). This study also included an
active treatment comparison with yohimbine, an alpha-2
adrenoceptor antagonist (5.4 mg daily). Yohimbine was also
studied at a dose of 5.4 mg three times daily in a another trial
with 33 participants (Jacobsen 1996).
7. Ephedrine was investigated in one study (Meston 2004).
8. Two different doses of maca root extract were compared in
one study (Dording 2008).
Change in antidepressant prescription
One study assessed changing from an SSRI to an antidepressant,
nefazodone, with a different mode of action (Ferguson 2001).
Other approaches
No studies were identified that assessed the use of drug holidays,
psychological interventions, or mechanical devices to treat sexual
dysfunction.
Outcomes
1) Measures of sexual function, dysfunction and satisfaction
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The trials used a variety of outcomemeasures to assess initial sexual
function and response to treatment. These included both self-as-
sessment and externally-rated measures. The scales used included:
1. International Index of Erectile Function (IIEF; Rosen
1997).
2. Arizona Sexual Experiences Scale (ASEX; McGahuey 2000).
3. Changes in Sexual Functioning Questionnaire (CSFQ;
Clayton 1997).
4. Erectile Dysfunction Inventory of Treatment Satisfaction
(EDITS; Althof 1999).
5. General Assessment Questions (GAQ; Evliyao lu 2011).
6. Sexual Side Effects Scale (SSES; Nelson 2001).
7. Brief Index of Sexual Functioning for Women (BISF-W;
Taylor 1994).
8. Feiger Sexual Function and Satisfaction Questionnaire
(FSFSQ; Feiger 1996).
9. Udvalg fur Kliniske Undersogelser side effect rating scale
(UKU; Lingjaerde 1987).
10. Massachussetts General Hospital-Sexual Functioning
Questionnaire (MGH-SFQ; Labbate 2001).
11. Clinical Global Impression Scale adapted for Sexual
Function (CGI-SF; Guy 1976).
12. The Physician’s Rating of Sexual Dysfunction Symptoms
(PRSDS; Ferguson 2001).
13. A modified version of the Rush-Presbyterian Sexual
Function Inventory (R-SFI; Ferguson 2001).
14. Interviewer Rating of Sexual Dysfunction, a semi-
structured interview (Michelson 2000).
15. Visual analogue scales (Bernik 2004; Michelson 2000).
16. Investigator-devised measures (Kang 2002; Wheatley
2004).
2) Measures of psychiatric symptoms
Depressive symptoms were measured using the Hamilton Rating
Scale for Depression (HAM-D; Hamilton 1960), Clinical Global
Impression, and Beck Depression Inventory (Beck 1961).
Anxiety symptoms were measured using the Hamilton Rating
Scale for Anxiety (HAM-A; Hamilton 1959), and the State-Trait
Anxiety Inventory (Spielberger 1983).
Excluded studies
A number of studies were excluded from the review (see
Characteristics of excluded studies). The most common reason for
exclusion was that randomised allocation was not employed, or it
was not established that the sexual dysfunction was attributable to
use of antidepressants.
Ongoing studies
Six studies were identified that are ongoing, or yet to report (see
Characteristics of ongoing studies). It appears, frompublished trial
registers, that one ongoing study is investigating change of an-
tidepressant (Takeda 2011). The remaining studies are investigat-
ing trazodone (Chiang 2010), ropinirole (Hellerstein 2008), maca
root (Dording 2010), combinations of testosterone with sildenafil
or buspirone (Van Rooiji 2010), and Ginkgo biloba, sex therapy,
and a combination of the two (Meston 2008).
Studies awaiting classification
Four studies are awaiting classification (see Characteristics of
studies awaiting classification), and, if suitable, will be included in
future updates of this review.
New studies found at this update
The original version of this review included 15 studies with around
900 participants. The current version includes 23 studies with
1886 participants, so there has been a substantial increase in the
availability of data from randomised trials to address this area of
interest.
Risk of bias in included studies
Risk of bias judgements are presented graphically in Figure 2 and
Figure 3 with further details tabulated in the Characteristics of
included studies table.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
There was generally little information provided on methods used
for randomisation or used to maintain concealment of allocation.
Blinding
While most studies reported use of blinding, commonly a ’double-
blind’ design (Figure 2), the extent of blinding was well described
in aminority of studies.Meston 2004 described testing participant
blinding for effectiveness, and finding that nine out of 11 women
correctly identified the order of treatment received.
Incomplete outcome data
The majority of included studies did not include, or did not re-
port, inclusion of withdrawals or dropouts in analyses. Four of the
studies specified that they included withdrawals and dropouts in
analyses by carrying forward prior observations (Ferguson 2001;
Ginsberg 2001;Michelson 2002;Nurnberg 2003).None followed
upwithdrawals to obtain further outcome data. The data currently
available on dropout rates for Ginsberg 2001 refer to the total over
both the initial placebo-controlled period, and the second stage of
the trial in which all participants received sildenafil.
Selective reporting
It was unclear in the majority of studies whether there had been
selective reporting of data, since original study protocols were not
available. In some cases, only data from particular subscales or
questions within a larger scale were reported.
Effects of interventions
See: Summary of findings for the main comparison Sildenafil
versus placebo; Summary of findings 2Bupropion versus placebo
Comparison one: Addition of phosphodiesterase
inhibitor
1.1 Sildenafil versus placebo
Six trials were identified that compared the effect of augmenting
antidepressant treatment with sildenafil or placebo. A newer trial
in men with erectile dysfunction, Fava 2006, was added to the
two trials included in the original version of this review (Ginsberg
2001; Nurnberg 2003). Two trials in women were identified (
Nurnberg 2002; Nurnberg 2008), but outcome data were only
available from one (Nurnberg 2008). A ’Summary of findings’
table is available (Summary of findings for the main comparison).
1.1.1 Effect on severity of the identified sexual dysfunction
For men, ratings of erectile dysfunction showed a benefit of silde-
nafil over placebo (Figure 4). Data from two studies found those
receiving sildenafil scored better than those receiving placebo on
questions from the IIEF regarding ability to achieve erection (MD
1.04, 95%CI 0.65 to 1.44; I2 = 34%) andmaintain erection (MD
1.18, 95% CI 0.78 to 1.59; I2 = 53%) (Analysis 1.1) (Fava 2006;
Nurnberg 2003). The remaining study in men found total ED-
ITS scores also favoured sildenafil (MD 21.60, 95% CI 4.30 to
38.90) (Analysis 1.2) (Ginsberg 2001). The I2values reported are
consistent with moderate statistical heterogeneity between studies
on the IIEF ratings.
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Figure 4. Forest plot of comparison 1: sildenafil vs placebo, outcome: 1.1 endpoint International Index of
Erectile Function (IIEF) scores
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For women, ratings of overall sexual dysfunction with the clin-
ician-rated CGI-SF favoured sildenafil (MD -0.80, 95% CI -
1.20 to -0.40) (Analysis 1.3), but results with the participant-
rated ASEX were consistent with benefits from either sildenafil or
placebo (MD -0.50, 95% CI -2.24 to 1.24) (Analysis 1.5).
1.1.2 Effect on sexual satisfaction and functioning
Similar effects of sildenafil were observed for men (Nurnberg
2003), and women (Nurnberg 2008), on the CGI-SF (RR 0.44,
95%CI0.33 to 0.58) (Analysis 1.4). ASEX scores from two studies
in men favoured sildenafil (MD -4.62, 95% CI -6.29 to -2.95;
Figure 5) (Analysis 1.5) (Ginsberg 2001; Nurnberg 2003). This
appears to differ from the uncertain effect found for women as
noted above. In the study in women from which data are available
(Nurnberg 2008), no difference was observed between sildenafil
andplacebo in endpoint total scores and subscales of SFQ (Analysis
1.14), and UNM-SFI (Analysis 1.15).
Figure 5. Forest plot of comparison 1: sildenafil vs placebo, outcome: 1.5 endpoint Arizona Sexual
Experience Scale (ASEX) total scores
In one study sildenafil was associated with improved scores on
the MGH-SFQ for total score and all domains (Analysis 1.7) (
Nurnberg 2003). The IIEF, total score, and several subdomains
showed benefit from sildenafil (Analysis 1.1), although increased
sexual desire was not demonstrated (MD 0.50, 95% CI -0.38 to
1.38). In another study (Fava 2006), GEQ responses indicated
improvement in erections and ability to have satisfactory sexual
intercourse (Analysis 1.12; Analysis 1.13).
1.1.3 Dropout rates
Reported dropout rates were consistent with effects favouring ei-
ther sildenafil or placebo (RR0.68, 95%CI 0.41 to 1.14) (Analysis
1.9).
1.1.4 Change in the primary psychiatric condition
From the two trials that provided data, endpoint HAM-D scores
tended to favour sildenafil but could not exclude a benefit of
placebo (MD -0.94, 95% CI -1.94 to 0.07) (Analysis 1.10); a
similar pattern was seen when analysed dichotomously for loss
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of remission from depression (RR 0.33, 95% CI 0.04 to 3.09)
(Analysis 1.11).
1.2 Tadalafil versus placebo
One study was identified that compared the effect of treatment
with tadalafil or placebo alongside antidepressant medication (
Evliyao lu 2011).
1.2.1 Effect on severity of the identified sexual dysfunction
Those receiving tadalafil were more likely than those on placebo
to report improved erectile function on the GAQ (RR 11.50, 95%
CI 3.03 to 43.67) (Analysis 2.1). IIEF data from Evliyao lu 2011
are not currently available in a suitable form for meta-analysis, but
qualitatively they suggest an effect on this measure for tadalafil
compared to placebo.
1.2.2 Effect on sexual satisfaction and functioning
Results from use of the Sexual Encounter Profile (SEP) diary mean
that a benefit of placebo could not be excluded (Analysis 2.2),
including rates of overall satisfaction (RR 6.00, 95% CI 0.78 to
46.29).
1.2.3 Dropout rates
Overall rates of early discontinuation were consistent with benefits
for tadalafil or placebo (RR 0.36, 95% CI 0.04 to 3.24) (Analysis
2.3), as were rates of discontinuation for apparent lack of efficacy
(RR 0.36, 95% CI 0.04 to 3.24). No dropouts were attributed to
adverse effects in either group.
1.2.4 Change in the primary psychiatric condition
No data were available on changes in the primary psychiatric con-
dition.
Comparison two: Addition of bupropion
2.1 Bupropion versus placebo
There are nowdata available fromfive trials, with 579 participants,
comparing the effect of augmenting antidepressant treatment with
bupropion or placebo (Clayton 2004; DeBattista 2005; Masand
2001; Safarinejad 2010; Safarinejad 2011). A ’Summary of find-
ings’ table is available (Summary of findings 2).
2.1.1 Effect on severity of the identified sexual dysfunction
Endpoint data for the total scores on rating scales used to iden-
tify sexual dysfunction were available from three studies (Clayton
2004; Safarinejad 2010; Safarinejad 2011), which gave a stan-
dardised mean difference (SMD) of 1.60 (95% CI 1.40 to 1.81)
favouring bupropion over placebo (Figure 6) (Analysis 3.1). There
was a high level of statistical inconsistency identified in this analy-
sis (I2 = 86%), which appears to be driven by the contrast between
the striking effect sizes reported in two studies (SMD 1.76, 95%
CI 1.45 to 2.07; Safarinejad 2010: and SMD 1.73, 95% CI 1.41
to 2.05; Safarinejad 2011), and a more modest trend in the third
(SMD 0.50, 95% CI -0.11 to 1.12; Clayton 2004). The reasons
for this inconsistency are unclear.
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Figure 6. Forest plot of comparison 3: bupropion vs placebo, outcome: 3.1 endpoint scale total scores
Response rates from two studies (DeBattista 2005;Masand 2001),
defined as 50% reduction in ASEX score, were consistent with
greater effects of either bupropion or placebo (RR 0.62, 95% CI
0.09 to 4.41; Figure 7) (Analysis 3.2), while one study found
that women taking bupropion were more likely to achieve a two-
point reduction on CGI-SF scores than those taking placebo (RR
186.73, 95% CI 11.74 to 2969.23) (Analysis 3.2) (Safarinejad
2011).
Figure 7. Forest plot of comparison 3: bupropion vs placebo, outcome: 3.2 response (as defined by study)
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2.1.2 Effect on sexual satisfaction and functioning
Endpoint CGI-SF scores from two studies favoured bupropion
(MD -1.74, 95% CI -1.87 to -1.61) (Analysis 3.8) (Safarinejad
2010; Safarinejad 2011). For men taking part in Safarinejad
2010, total scores and all subscales from IIEF, ASEX, and EDITS
scales favoured bupropion over placebo (IIEF Analysis 3.3; ASEX
Analysis 3.9; EDITS Analysis 3.10; Analysis 3.11). For women
taking part in Safarinejad 2011, FSFI total score and subscales
other than pain favoured bupropion (Analysis 3.4).
In Clayton 2004 CSFQ total scores were consistent with a greater
effect of either bupropion or placebo (MD 4.50, 95% CI -0.89 to
9.89) (Analysis 3.5), as were subscales other than desire/frequency,
where a benefit of bupropion was observed (MD 0.88, 95% CI
0.21 to 1.55).
2.1.3 Dropout rates
There was no statistically significant difference in dropout rates
between bupropion and placebo (RR 1.08, 95% CI 0.67 to 1.72)
(Analysis 3.6).
2.1.4 Change in the primary psychiatric condition
One trial reported endpoint HAM-D scores (Clayton 2004), and
found no significant difference between the groups (MD -0.60,
95% CI -2.62 to 1.42) (Analysis 3.7).
Comparison three: Change of antidepressant
3.1 Nefazodone versus sertraline
One trial compared the effect of changing antidepressant to nefa-
zodonewith effect of restarting sertraline after a two-weekwashout
period inwhich sertraline-induced sexual dysfunctionhad resolved
(Ferguson 2001).
3.1.2 Effect on severity of the identified sexual dysfunction
On a physician-rated measure (PRSDS), sexual dysfunction was
significantly less likely to re-emerge on treatment with nefazodone
compared with restarting sertraline (RR 0.34, 95% CI 0.19 to
0.60) (Analysis 4.1). Thismeans the number needed to treat for an
additional beneficial outcome (NNTB) with nefazodone, that is
for one additional person to avoid re-emergence of sexual dysfunc-
tion, was two (95% CI 2 to 4). This benefit of using nefazodone
was seen by the end of the first week of treatment (Analysis 4.1).
3.1.2 Effect on sexual satisfaction and functioning
Differences in participant-rated overall sexual satisfaction did not
achieve statistical significance (MD17.22, 95%CI -4.57 to 39.01)
(Analysis 4.2).
3.1.3 Dropout rates
No significant difference was noted between groups in overall
dropout rates, RR 0.83 (95% CI 0.43 to 1.60) nor in dropouts
attributed to adverse effects, RR 0.46 (95% CI 0.17 to 1.25).
3.1.4 Change in the primary psychiatric condition
There was no significant difference in HAM-D between the two
groups at the end of the trial (MD -1.57, 95% CI -4.51 to 1.37).
Comparison four: Addition of Ginkgo biloba
4.1 Ginkgo biloba versus placebo
Two studies compared the effect of augmenting antidepressant
treatment with Ginkgo biloba or placebo (Kang 2002; Wheatley
2004).
4.1.1 Effect on severity of the identified sexual dysfunction
There was no significant difference in endpoint sexual dysfunction
between the groups on most questions of a nine-item question-
naire in one study (Kang 2002) . On the ’satisfaction to orgasm’
question, scores were better in the placebo arm (MD -1.12, 95%
CI -2.00 to -0.24). Only data from the five items assessed in both
genders was provided in sufficient detail for analysis.
In the second study (Wheatley 2004), total scores on an investi-
gator-developed scale of sexual dysfunction were compatible with
a benefit of either placebo or Ginkgo biloba (MD 3.80, 95% CI -
1.94 to 9.54) (Analysis 5.2).
4.1.2 Effect on sexual satisfaction and functioning
No other data on sexual satisfaction or functioning were reported.
4.1.3 Dropout rates
There was no significant difference in the rate of dropouts be-
tween the two arms of Kang 2002 (RR 1.33, 95% CI 0.51 to
3.43) (Analysis 5.3). There was an overall dropout rate of 22% in
Wheatley 2004, but the distribution of dropouts between treat-
ment arms was unclear.
4.1.4 Change in the primary psychiatric condition
No data were available on changes in the primary psychiatric con-
dition from Kang 2002. Ratings of depression and anxiety symp-
toms were obtained by Wheatley 2004, but sufficient details are
not available for analysis here.
Comparison five: Addition of granisetron
5.1 Granisetron versus placebo
Two trials compared augmentation of antidepressant treatment
with granisetron to the addition of placebo (Jespersen 2004;
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Nelson 2001). Data from Nelson 2001 were derived from both
cross-over periods of the trial.
5.1.1 Effect on severity of the identified sexual dysfunction
In the Nelson 2001 trial both groups had similar change from
baseline on SSES scores (MD 0.10, 95% CI -2.22 to 2.42). In the
Jespersen 2004 trial, total scores on both ASEX and FSFSQ were
consistent with greater benefit from either granisetron or placebo
(ASEXMD 7.90, 95%CI -1.87 to 17.67: FSFSQMD 1.60, 95%
CI -5.46 to 8.66).
5.1.2 Effect on sexual satisfaction and functioning
In Jespersen 2004, most item scores on both ASEX and FSFSQ
were consistent with greater benefit from either granisetron or
placebo (Analysis 6.2; Analysis 6.3). Where items did favour one
agent, placebo performed better than granisetron (FSFSQ items
1 and 2; and ASEX orgasm satisfaction).
5.1.3 Dropout rates
There was no statistically significant difference in dropout rates
between the two groups in the Jespersen 2004 trial (RR 6.67, 95%
CI 0.39 to 114.78) (Analysis 6.4). There was an overall dropout
rate of 35% in Nelson 2001, but the distribution of the dropouts
between treatments was not clear.
5.1.4 Change in the primary psychiatric condition
Rates of recurrence of mood symptoms were consistent with ben-
efit of either agent in the Nelson 2001 study (RR 2.87, 95%CI
0.12 to 66.75) (Analysis 6.5). In the Jespersen 2004 study it was
reported that CGI for depressive symptoms did not differ between
groups, but insufficient details were available for analysis.
Comparison six: Addition of a 5HT1A receptor
agonist
6.1 VML-670 versus placebo
Only the Baldwin 2008 study compared augmentation of antide-
pressant treatment with VML-670 to the addition of placebo.
6.1.1 Effect on severity of the identified sexual dysfunction
By the end of the trial, rates of absence of sexual dysfunction,
defined by ASEX, were consistent with benefits of either VML-
607 or placebo (RR 1.24, 95% CI 0.86 to 1.77) (Analysis 7.1),
as were rates of improvement defined by CGI (RR 1.24, 95% CI
0.71 to 2.17) (Analysis 7.2).
6.1.2 Effect on sexual satisfaction and functioning
ASEX total scores were not presented with sufficient detail for
analysis in this review. Items of the ASEX were mostly consistent
with benefits of either VML-607 or placebo (Analysis 7.3), with
the exception thatmen randomised toVML-670 reported a greater
improvement in erectile function (MD -0.40, 95% CI -0.80 to
0.00).
6.1.3 Dropout rates
No significant difference was noted between groups in overall
dropout rates (RR 0.97, 95% CI 0.56 to 1.68), or in dropouts
attributed to adverse effects (RR 2.32, 95% CI 0.75 to 7.21)
(Analysis 7.4).
6.1.4 Change in the primary psychiatric condition
Insufficient details on HAM-D scores were available for analysis
in this review.
6.2 Buspirone versus placebo
One trial compared the effect in women of augmenting antide-
pressant treatment with buspirone or placebo (Michelson 2000).
6.2.1 Effect on severity of the identified sexual dysfunction
Sexual dysfunction was identified for study inclusion by clinician-
rated global impression, but insufficient details of the results were
presented to allow for analysis in this review.
6.2.2 Effect on sexual satisfaction and functioning
Changes in ratings on visual analogue scales of aspects of sexual
functioning were consistent with benefits for either buspirone or
placebo (Analysis 8.1), as was change in a summary measure of
overall functioning (MD 3.10, 95% CI -38.33 to 44.53).
6.2.3 Dropout rates
No significant difference was noted between groups in overall
dropout rates (RR 2.00, 95% CI 0.20 to 20.41) (Analysis 8.2)
6.2.4 Change in the primary psychiatric condition
Visual analogue scale ratings of mood (MD 0.80, 95% CI -7.61
to 9.21) and energy (MD 5.30, 95% CI -3.88 to 14.48) (Analysis
8.1) were consistent with benefits for either buspirone or placebo.
Insufficient details on specific depression and anxiety rating scale
scores were presented to permit analysis in this review.
Comparison seven: Addition of bethanecol
7.1 Bethanecol versus placebo
One study compared augmentation of antidepressant treatment
with bethanecol against augmentation with placebo (Bernik
2004).
7.1.1 Effect on severity of the identified sexual dysfunction
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Those receiving bethanecol reported higher scores than those re-
ceiving placebo on a six-point visual analogue scale of orgasmic
function (MD 3.40, 95% CI 0.99 to 5.81) (Analysis 9.1).
7.1.2 Effect on sexual satisfaction and functioning
Data on erectile function were obtained, but not reported.
7.1.3 Dropout rates
Two of the 12 participants dropped out during the study, but it
was unclear from which treatment group(s).
7.1.4 Change in the primary psychiatric condition
One participant (1/12) developed a depressive episode during the
study, but it was unclear which treatment s/he was receiving at the
time.
Comparison eight: Addition of a 5HT2 receptor
antagonist
One trial compared augmentation of antidepressant treatment in
women with agents including placebo and two 5HT2 receptor
antagonists, olanzapine andmirtazapine (Michelson 2002). These
comparisons against placebo are considered separately below:
8.1 Olanzapine versus placebo
8.1.1 Effect on severity of the identified sexual dysfunction
The group receiving olanzapine reported a greater improvement
on a scale of overall sexual satisfaction completed at interview (MD
-0.70, 95% CI -1.17 to -0.23). Other measures of sexual function
completed at the same time were consistent with benefits for either
olanzapine or placebo (Analysis 10.1).
8.1.2 Effect on sexual satisfaction and functioning
Diary ratings were all consistent with benefits for either olanzapine
or placebo (Analysis 10.2).
8.1.3 Dropout rates
There was an overall dropout rate of 27%, but the distribution
of dropouts between treatment group(s) was unclear. Dropouts
attributed to adverse effects were consistent with benefits for either
olanzapine or placebo (RR 3.59, 95% CI 0.80 to 16.21) (Analysis
10.3).
8.1.4. Change in the primary psychiatric condition
Change in mood did not differ between groups on diary ratings
(MD0.10, 95%CI -0.41 to 0.61) (Analysis 10.2).HAM-D scores
were collected, but insufficient details were provided to allow for
analysis.
8.2 Mirtazapine versus placebo
8.2.1 Effect on severity of the identified sexual dysfunction
Participant ratings of sexual function completed at interview were
consistent with benefits for eithermirtazapine or placebo (Analysis
11.1), including overall sexual satisfaction (MD 0.10, 95% CI -
0.29 to 0.49).
8.2.2 Effect on sexual satisfaction and functioning
Diary ratings of overall sexual function were consistent with ben-
efits for either mirtazapine or placebo (MD -1.30, -5.71 to 3.11),
as were other diary ratings of sexual function (Analysis 11.2).
Kinsey Structured Interview ratings of sexual satisfaction were bet-
ter in those receiving placebo than mirtazapine (MD 0.60, 95%
CI 0.19 to 1.01) (Analysis 11.3).
8.2.3 Dropout rates
There was an overall dropout rate of 27%, but the distribution of
the dropouts between treatments was unclear. More participants
dropped out of the mirtazapine group than the placebo group
because of adverse effects (RR 6.50, 95% CI 1.56 to 27.07) (
Analysis 11.4).
8.2.4 Change in the primary psychiatric condition
Change in mood did not differ between groups on diary ratings
(MD -0.40, 95% CI -0.93 to 0.13). Changes in ratings of energy
were better in those receiving mirtazapine (MD -0.70, 95% CI -
1.38 to -0.02) (Analysis 11.2). HAM-D scores were collected, but
insufficient details were provided to allow for analysis.
Comparison nine: Yohimbine versus placebo
One trial compared augmentation of antidepressant treatment in
women with yohimbine or placebo (Michelson 2002), and pro-
vided outcome data for this review. A second study has also been
performed (Jacobsen 1996), but data were not available in a form
suitable for analysis in this review.
9.1. Effect on severity of the identified sexual dysfunction
Participant ratings of sexual function completed at interview were
consistent with benefits for either yohimbine or placebo (Analysis
12.1), including overall sexual satisfaction (MD -0.30, 95% CI -
0.79 to 0.19).
9.2. Effect on sexual satisfaction and functioning
Diary ratings of overall sexual function were consistent with ben-
efits for either yohimbine or placebo (MD 1.20, 95% CI -3.24
to 5.64), as were other diary ratings of sexual function (Analysis
12.2).
9.3. Dropout rates
There was an overall dropout rate of 27%, but the distribution
of dropouts between treatment group(s) was unclear. Dropouts
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attributed to adverse effects were consistent with benefits for either
yohimbine or placebo (RR 2.23, 95% CI 0.43 to 11.43) (Analysis
12.3).
9.4. Change in the primary psychiatric condition
Change in mood did not differ between groups on diary ratings
(MD0.10, 95%CI -0.41 to 0.61) (Analysis 12.2).HAM-D scores
were collected, but insufficient details were provided to allow for
analysis.
Comparison ten: Amantadine versus placebo
One trial compared augmentation of antidepressant treatment in
women with amantadine or placebo (Michelson 2000).
10.1. Effect on severity of the identified sexual dysfunction
Sexual dysfunction was identified for study inclusion by clinician-
rated global impression, but insufficient details of the results were
presented to allow for analysis here.
10.2. Effect on sexual satisfaction and functioning
Changes in ratings on visual analogue scales of aspects of sexual
functioning were consistent with benefits for either amantadine
and placebo (Analysis 13.1).
10.3. Dropout rates
No significant difference was noted between groups in overall
dropout rates (RR 1.11, 95% CI 0.07 to 16.47) (Analysis 13.2).
10.4. Change in the primary psychiatric condition
Participants randomised to amantadine reported a greater increase
in ratings of both mood (MD 8.10, 95% CI 1.23 to 14.97) and
energy (MD 12.70, 95%CI 5.30 to 20.10) (Analysis 13.1). Insuf-
ficient details on specific depression and anxiety rating scale scores
were presented to allow for analysis here.
Comparison eleven: Ephedrine versus placebo
One trial compared the effect of augmenting antidepressant treat-
ment with ephedrine or placebo (Meston 2004). Data were de-
rived from both cross-over periods of the trial.
11.1. Effect on severity of the identified sexual dysfunction
Ratings at the end of treatment on the BISF-W were consistent
with benefits from either ephedrine or placebo (Analysis 14.1).
11.2. Effect on sexual satisfaction and functioning
No measures to assess sexual satisfaction and functioning were
employed in this trial.
11.3. Dropout rates
There was an overall dropout rate of 34%, but the distribution of
dropouts between treatment group(s) was unclear.
11.4. Change in the primary psychiatric condition
Ratings of depression were made, but insufficient details were pre-
sented to allow for analysis here.
Comparison twelve: Maca root low dose (1.5 g) versus maca
root high dose (3 g)
One study was identified that assessed the effects of two different
doses of maca root on antidepressant-induced sexual dysfunction
(Dording 2008).
12.1. Effect on severity of the identified sexual dysfunction
Participants randomised to either dose of maca root reported sim-
ilar endpoint ratings by ASEX total score (MD -0.80, 95% CI -
6.49 to 4.89) (Analysis 15.1) and MGH-SFQ total score (MD -
2.00, 95% CI -7.69 to 3.69) (Analysis 15.2).
12.2. Effect on sexual satisfaction and functioning
Similarly, ratings of sexual desire items from both ASEX (MD
0.30, 95%CI -1.38 to 1.98) (Analysis 15.1) andMGH-SFQ (MD
-0.10, 95%CI -1.62 to 1.42) (Analysis 15.2) were similar between
groups.
12.3. Dropout rates
Rates of overall dropout did not differ between groups (RR 1.50,
95% CI 0.60 to 3.74) (Analysis 15.3).
12.4. Change in the primary psychiatric condition
The HAM-D total endpoint score was not significantly different
between the groups (MD -2.50, 95% CI -7.98 to 2.98) nor was
the HAM-A total endpoint score (MD -0.40, 95% CI -3.15 to
2.35) (Analysis 15.4).
Subgroup and sensitivity analyses
Due to the small number of studies in each comparison we were
unable to conduct the planned subgroup and sensitivity analyses.
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D I S C U S S I O N
Summary of main results
Twenty-three trials involving 1886 people met the inclusion cri-
teria for the updated review. The original version of this review
included 15 studies with around 900 participants randomised, so
there has been a substantial increase in the data available from
randomised trials to address this area of interest. This update has
included both increased data for previously identified strategies
(addition of sildenafil or bupropion) and trials of new agents for
this indication. All except one trial (Ferguson 2001) assessed the
addition of further medication to treat the sexual dysfunction.
We were unable to do the intended subgroup analyses by gender,
but these are summarised descriptively here to facilitate interpre-
tation.
Men
In men, data for the phosphodiesterase inhibitors sildenafil (three
studies, 255 participants; see Summary of findings for the main
comparison) and tadalafil (one study, 54 participants) indicated
that they led to a greater improvement in erectile function than
placebo. The estimates of treatment effect observed are similar to
those reported for their use in erectile dysfunction due to other
causes (Fink 2002; Carson 2004).
In men, addition of higher dose bupropion has also shown ben-
efit (see Summary of findings 2), but this is primarily shown in
a single study (234 participants; Safarinejad 2010). Replication
of this effect is likely to increase confidence in this finding. The
magnitude of effect seen on total IIEF score (MD 20.10, 95% CI
17.14 to 23.06) (Analysis 3.3) was similar to that seen in studies
of sildenafil (MD 19.36, 95% CI 15.00 to 23.72) (Analysis 1.1).
There are also some promising data from a small cross-over trial
of bethanecol suggesting benefit for men with antidepressant-in-
duced ejaculatory delay or anorgasmia rather than erectile dys-
function (Bernik 2004). Replication in further studies is likely to
be necessary for clinicians and patients to have confidence in this
effect.
Women
For women it remains uncertain whether sildenafil is more effec-
tive than placebo, but outcome data are only available from one
study (Nurnberg 2008). We have identified a larger unpublished
study (Nurnberg 2002) - if results from this second study were to
become available, it would be expected to reduce this uncertainty
substantially.
Data from studies of bupropion 150 mg twice daily indicate
a benefit over placebo. These included a study that predomi-
nantly included women (Clayton 2004), and one solely in women
(Safarinejad 2011). However, response rates in two studies of
bupropion 150 mg once daily were consistent with superiority of
either bupropion or placebo. The two-point improvement in CGI
taken as a measure of response in Safarinejad 2011 is equivalent
to an improvement in rating from ’markedly’ to ’mildly’ impaired
function, which may be a clinically significant change.
Both sexes
Other augmentation strategies studied failed to show significant
improvements in sexual dysfunction compared with placebo
One trial involving 75 participants of both genders with sexual
dysfunction due to sertraline assessed the effect of changing the an-
tidepressant. Switching to nefazodone was significantly less likely
to result in the re-emergence of sexual dysfunction than restarting
sertraline, and was not associated with any worsening of depres-
sion. However, since nefazodone is no longer available for use, this
strategy is now of limited usefulness.
Adverse effects
We hypothesised that management strategies for antidepressant-
induced sexual dysfunctionmight differ in acceptability or be asso-
ciated with a worsening of the condition for which antidepressants
were originally being taken. We have identified no data for any
of the strategies assessed here that indicated they led to a worsen-
ing of psychiatric symptoms. However, the relatively small num-
bers assessed for many of the interventions studied means that the
possibility of such an effect cannot confidently be excluded in all
cases.
Rates of dropout from studies with different treatments were
not clearly presented in all cases. From the available data, only
one intervention was associated with an increase in people drop-
ping out of the study, which was augmentation with mirtazapine
(Michelson 2002). However, the analysis of this four-arm study
does not correct for themultiple statistical comparisons that result,
and therefore the 95% confidence intervals presented may over-
estimate the confidence with which this effect has been shown.
Further randomised trial data may act to reduce this uncertainty.
Overall completeness and applicability of
evidence
The available data mostly investigate the strategy of adding ad-
ditional medication to counteract antidepressant-induced sexual
dysfunction. There is an absence of randomised data that assesses
switching to currently-available antidepressant agents with lower
rates of sexual adverse effects, the role of psychological or me-
chanical interventions (Hawton 1995), or of techniques such as
drug holidays. There is a particular need for more evidence to
guide treatment of antidepressant-induced sexual dysfunction in
women. The ongoing studies identified suggest that this limitation
of the evidence-base will be only partially be addressed in the fore-
seeable future. Of the six studies identified, only one is investigat-
ing change of antidepressant (Takeda 2011), and only one other
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is investigating Ginkgo biloba, sex therapy, and a combination of
the two (Meston 2008).
Quality of the evidence
Twenty-three trials involving 1886 people were included in this
review. Many studies were unclear in their reporting of methods,
which leaves uncertainty regarding the extent to which their re-
sults are subject to bias (see Figure 2). Use of a double-blind design
was commonly reported, but there was generally little informa-
tion provided on methods used for randomisation or to maintain
concealment of allocation. Studies may have been vulnerable to
reporting bias, since original study protocols were not available,
and, in some cases, only data from particular subscales or ques-
tions within a larger scale were reported.
There is now a strong and internally consistent evidence base for
the use of phosphodiesterase inhibitors for antidepressant-induced
erectile dysfunction in men. For women with antidepressant-in-
duced sexual dysfunction, the addition of bupropion at higher
doses appears to be the most promising approach studied so far,
however, unexplained inconsistencies in effects between studies
remain, reducing the confidence with which this strategy can be
advocated.
Potential biases in the review process
While we have made efforts to be comprehensive in our methods
to identify all published studies, given the small numbers of studies
that investigatedmost of the strategies assessed, the presence of any
unpublished trials could have substantial effects on estimates of
effect. In some cases, only results fromparticular items or subscales
within ratings scales are available. It is likely that this could act to
bias estimates of effect obtained, increasing apparent effectiveness.
The investigation of multiple strategies and often multiple out-
comes for each strategy within this review will have increased the
risk of reporting false positive findings of effectiveness.
Agreements and disagreements with other
studies or reviews
The Cochrane Review on the management of sexual dysfunction
due to antipsychotic drug therapy similarly found some support for
the addition of sildenafil in men (Schmidt 2012), but the evidence
available came from only one small study (32 participants). We are
not aware of any non-Cochrane systematic reviews on this topic.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The evidence currently available is rather limited. For men with
antidepressant-induced erectile dysfunction, the addition of silde-
nafil or tadalafil appears to be an effective strategy, and there are
some promising data for bupropion. For women with antidepres-
sant-induced sexual dysfunction, the addition of bupropion at
higher doses appears to be the most promising approach studied
so far.
Implications for research
Further randomised trials are required. There is a particular need
for more evidence to guide treatment of antidepressant-induced
sexual dysfunction in women. Addition of bupropion to existing
treatment warrants further study. Randomised trials could assess
approaches for which there is currently an absence of evidence,
including: switching to currently-available antidepressant agents
with lower rates of sexual adverse effects, the role of psycholog-
ical or mechanical interventions, or of techniques such as drug
holidays. Outcome assessments using standardised ratings scales
should be included.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Baldwin 2008
Methods Double-blind, multicentreD (37 sites), parallel group, 4-week duration
Participants 288 adults (ages 22-67 years) randomised (84 men, 204 women)
Inclusion criteria: sexually active at least once a week; sexual dysfunction treatment-
emergent; ASEX score 19 or more; stable dosage of fluoxetine or paroxetine for at least
8 weeks prior to screening and for 3 months
Exclusion criteria: HAM-D score of 12 or more
Interventions 1. VML-670 (300 µg once daily) or,
2. Placebo daily
Outcomes Assessed with following scales: ASEX, CGI, HAM-D
Notes 37 UK primary care sites
VML-670 is a 5-HT1A receptor agonist
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated schedule
Allocation concealment (selection bias) Unclear risk -
Blinding (performance bias and detection
bias)
All outcomes
Low risk All study personnel and participants were
blinded to treatment assignment for dura-
tion of the study
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All study personnel and participants were
blinded to treatment assignment for dura-
tion of the study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All study personnel and participants were
blinded to treatment assignment for dura-
tion of the study
Incomplete outcome data (attrition bias)
All outcomes
Low risk -
Selective reporting (reporting bias) Unclear risk -
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Bernik 2004
Methods Double-blind, 2 period cross-over design, 2 weeks of active treatment
Participants 12 men (aged 18-65 years) randomised
Inclusion criteria: In remission from panic disorder; treated with clomipramine; ejacu-
latory delay or anorgasmia (no participants with erectile dysfunction)
Interventions 1. Bethanecol chloride 20 mg as needed (taken 45 minutes before sexual intercourse on
up to 2 occasions in each 2-week period), or
2. Placebo
Outcomes Changes in VAS sexual function scale
Notes Trial performed in Brazil
Bethanecol has mixed central and peripheral cholinergic and adrenergic effects
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk -
Allocation concealment (selection bias) Unclear risk -
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’Double blind’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’Double blind’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ’Double blind’
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk -
Selective reporting (reporting bias) Unclear risk -
Clayton 2004
Methods Double-blind, parallel-arm, multicentred (3 sites), 4-weeks duration
Participants 55 adults (aged 18-45 years) randomised (48 women, 7 men).
Includsion criteria:DSM-IVdepressionwith sustained remission; developed orworsened
sexual problems on current SSRI treatment
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Clayton 2004 (Continued)
Interventions 1. Bupropion SR 150 mg (once daily for 3 days, increasing to twice daily if tolerated) in
addition to SSRI, or
2. Placebo twice daily, in addition to SSRI
Outcomes CSFQ, HAM-D
Notes USA sites
Bupropion is thought to act by dual inhibition of norepinephrine and dopamine reuptake
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk -
Allocation concealment (selection bias) Unclear risk -
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’Double blind’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’Double blind’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ’Double blind’
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete data
Selective reporting (reporting bias) Unclear risk -
DeBattista 2005
Methods Double-blind, parallel-arm trial, 6-week duration
Participants 41 adults (aged 18-60 years) randomised (17 men, 24 women).
Inclusion criteria: stable dose of fluoxetine, paroxetine, citalopram or sertraline for at
least 6 weeks; sexual side effects which participants believed were temporally related to
the antidepressant use; ASEX score of at least 15
Interventions 1. Bupropion SR 150 mg once daily for six weeks, in addition to current SSRI, or
2. Placebo for six weeks, in addition to current SSRI
Outcomes ASEX, HAM-D, Beck Depression Inventory
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DeBattista 2005 (Continued)
Notes Trial performed in USA
Bupropion is thought to act by dual inhibition of norepinephrine and dopamine reuptake
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk -
Allocation concealment (selection bias) Unclear risk -
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’Double blind’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’Double blind’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ’Double blind’
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk -
Selective reporting (reporting bias) High risk No outcome data reported for secondary
measures
Dording 2008
Methods Parallel group trial, 12 weeks of treatment
Participants 20 adults (3 men, 17 women)
Inclusion criteria: depression in remission (HAM-D < 10); SSRI-induced sexual dys-
function for at least 4 weeks (no sexual dysfunction before antidepressant, clear temporal
relationship between antidepressant and dysfunction)
Interventions 1. Maca root (Lepidium meyenii) extract 3.0 g/day, or
2. Maca root (L meyenii) extract 1.5 g/day
Outcomes ASEX, MGH-SFQ, HAM-D, HAM-A
Notes Trial performed in USA
Maca, also known as “Peruvian Ginseng,” is a plant traditionally used for medicinal
purposes
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Dording 2008 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk -
Allocation concealment (selection bias) Unclear risk -
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’Double blind’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’Double blind’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ’Double blind’
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Unclear risk -
Evliyao lu 2011
Methods Parallel group trial, 12-week duration
Participants 54 men (aged 23-74 years) randomised.
Inclusion criteria: sexual dysfunction emerged during antidepressant (SRI) treatment;
dysfunction continued for 4 weeks or more
Interventions 1. Tadalafil 20 mg, or
2. Placebo
Tadalafil or placebo taken 1 h before sexual activity, and not more than once daily
Outcomes IIEF; SEP diary; Global Assessment Questions
Notes Trial performed in Turkey
Tadalafil is a phosphodiesterase type 5 inhibitor
Risk of bias
Bias Authors’ judgement Support for judgement
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Evliyao lu 2011 (Continued)
Random sequence generation (selection
bias)
Unclear risk States ’randomly assigned’, but no details pro-
vided on method of sequence generation
Allocation concealment (selection bias) Unclear risk -
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’Participants, physicians and data collators were
unaware of the treatment assignment of the pa-
tients’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’Participants, physicians and data collators were
unaware of the treatment assignment of the pa-
tients’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ’Participants, physicians and data collators were
unaware of the treatment assignment of the pa-
tients’
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete data
Selective reporting (reporting bias) Low risk All outcomes described
Fava 2006
Methods Double-blind, parallel-arm trial, 6-week duration
Participants 142 men (aged 27-74 years) randomised.
Inclusion criteria: SSRI-associated erectile dysfunction (SexualHealth Inventory forMen
score > 20); no erectile dysfunction prior to antidepressant; DSM-IV major depressive
disorder currently in remission (HAM-D < 10); taking SRI for 8 weeks or more, and
stable dose for 4 weeks
Interventions 1. Sildenafil 50 mg daily initially then variable dose later (25-100 mg depending on
efficacy and tolerability), or
2. Placebo
Outcomes IIEF, Erectile Dysfunction Inventory of Treatment Satifisaction, Global Efficacy Ques-
tionnaire, HAM-D, Beck Anxiety Inventory
Notes Centres in USA, Germany, UK, Canada
Sildenafil is a phosphodiesterase inhibitor
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned using a computer algo-
rithm of random permuted blocks
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Fava 2006 (Continued)
Allocation concealment (selection bias) Unclear risk -
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’Double blind’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’Double blind’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ’Double blind’
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Unclear risk -
Ferguson 2001
Methods Double-blind, parallel-arm, multicentreD (9 sites) trial, 10-week duration
Participants 75 adults (aged 18-65 years) randomised (34 women, 38 men).
Inclusion criteria: DSM-III-R moderate or severe depressive episode; sexual dysfunction
due to sertraline; judged clinically stable and able to discontinue sertraline; all symptoms
of sexual dysfunction absent during placebo run-in phase
Interventions 1-week washout period when sertraline treatment suspended, then 7-10 day placebo lead
in, then:
1. Nefazodone 100 mg twice daily increasing to 200 mg after 1 week, or
2. Sertraline 50 mg once daily increasing to 100 mg after 1 week and placebo at night
Outcomes Physician’s rating of sexual dysfunction, modified version of Rush-Presbyterian Sexual
Function Inventory, HAM-D, CGI (for depressive symptoms)
Notes Trial performed in USA, 9 sites
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details of sequence generation method
provided
Allocation concealment (selection bias) Unclear risk -
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Ferguson 2001 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’Double blind’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’Double blind’
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk ’Double blind’
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Three of 75 participants randomised ex-
cluded from efficacy analyses
Selective reporting (reporting bias) Unclear risk -
Ginsberg 2001
Methods Double-blind, parallel-arm trial, 8-week duration
Participants 23 men (aged 30-64 years).
Inclusion criteria: clinically recovered mood or anxiety disorder; SSRI associated sexual
dysfunction (SSRI or venlafaxine); medications stable for 4 weeks prior and during study
Interventions 1. Sildenafil 50-100 mg once daily for 8 weeks, or
2. Placebo for 8 weeks
Outcomes IIEF, ASEX, Erectile Dysfunction Inventory of Treatment Satifsaction, Rigiscan
Notes Multicentred
Sildenafil is a phosphodiesterase inhibitor
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk -
Allocation concealment (selection bias) Unclear risk -
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’Double blind’
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Ginsberg 2001 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’Double blind’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ’Double blind’
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) High risk Not all outcomes reported (abstract, not
full publication)
Jacobsen 1996
Methods Cross-over design, 2 sequential 3-week trials
Participants 33 participants (11 men, 22 women).
Inclusion criteria: sexual dysfunction after starting SRI treatment; DSM-IV major de-
pression, bipolar disorder, or obsessive compulsive disorder; fluoxetine or sertraline taken
for at least 8 weeks prior to study entry
Interventions 1. Yohimbine 5.4 mg three times daily, or
2. Placebo three times daily
Outcomes 4-point scales for libido, orgasm, erection (men), mood, anxiety, sleep disturbance, gas-
trointestinal distress, flushing
Notes Trial performed in USA
Yohimbine blocks alpha-2 adrenoceptors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk -
Allocation concealment (selection bias) Unclear risk -
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’Double blind’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’Double blind’
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Jacobsen 1996 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ’Double blind’
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear whether more than 33 people ran-
domised
Selective reporting (reporting bias) Unclear risk -
Jespersen 2004
Methods Double-blind, parallel-arm trial, 14-day duration
Participants 12 women (age range unclear) randomised.
Inclusion criteria: antidepressant-induced sexual dysfunction; past diagnosis of depres-
sion (by MINI neuropsychiatric interview); no change in psychotropic treatment in pre-
vious 2 months; no comorbid psychiatric or medical disorder; no past history of sexual
dysfunction
Interventions 1. Granisetron (dose not specified), or
2. Placebo
Outcomes FSFSQ, ASEX, CGI ratings of depressive symptoms
Notes Trial performed in South Africa.
Granisetron is a 5-HT3 antagonist
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details of random sequence generation
provided
Allocation concealment (selection bias) Unclear risk -
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’Double blind’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’Double blind’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ’Double blind’
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Jespersen 2004 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Unclear risk -
Kang 2002
Methods Double-blind, parallel-arm, single-centre trial, 2-month duration
Participants 37 adults randomised (27 men, 10 women).
Inclusion criteria: DSM-IV substance-induced sexual dysfunction; antidepressant treat-
ment of depressive disorder (without psychotic features) or anxiety disorder; regular sex-
ual activity
Interventions 1. Ginkgo biloba (EGb761) 120 mg/day increasing to 160 mg/ day after 2 weeks, and
increasing to 240 mg/day after 4 weeks, or
2. Placebo
Outcomes Investigator-developed questionnaire, Beck Depression Inventory (Korean version),
State-Trait Anxiety Inventory
Notes Trial performed in South Korea
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Random number table’
Allocation concealment (selection bias) Unclear risk -
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’Double blind’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’Double blind’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ’Double blind’
Incomplete outcome data (attrition bias)
All outcomes
Low risk
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Kang 2002 (Continued)
Selective reporting (reporting bias) Unclear risk -
Masand 2001
Methods Double-blind, parallel-arm trial, 3-week duration
Participants 31 adults randomised (breakdown by gender unknown).
Inclusion criteria: receiving SSRI for at least 6 weeks; sexual dysfunction attributed to
SSRI (ASEX score: total score of 19 or more on the ASEX scale or any individual item
score > 5 or any 3 items equal to 4); HAM-D score < 10
Interventions 1. Bupropion SR 150 mg daily, or
2. Placebo
Outcomes ASEX, HAM-D, UKU side effects rating scale
Notes Trial performed in the USA
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk -
Allocation concealment (selection bias) Unclear risk -
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’Double blind’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’Double blind’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ’Double blind’
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Unclear risk -
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Meston 2004
Methods Double-blind, cross-over design, 8-week duration
Participants 29 women randomised.
Inclusion criteria: SSRI for depression; at least 10 weeks treatment; treatment otherwise
successful;
sexual dysfunctiononset not less than1week andnotmore than3months after beginning
SSRI; sexual dysfunction distinctly different from any noticed during depressed phase
Interventions 1. Ephedrine 50 mg once daily, or
2. Placebo
Treatments to be taken approximately 1 h before sexual activity
Outcomes BISF-W, Beck Depression Inventory
Notes Trial performed in USA
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information on sequence generation
method provided
Allocation concealment (selection bias) Unclear risk -
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’Double blind’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’Double blind’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ’Double blind’
Incomplete outcome data (attrition bias)
All outcomes
Low risk -
Selective reporting (reporting bias) Unclear risk -
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Michelson 2000
Methods Double-blind, parallel-arm, multicentred trial (3 sites), 8 weeks of treatment
Participants 61 women (aged 50 years or younger) randomised.
Inclusion criteria: stable dose of fluoxetine for at least 8 weeks; impaired orgasm or
sexual arousal or vaginal lubrication with onset after initiation of fluoxetine; CGI sexual
function score of at least 3, HAM-D score < 11
Interventions 1. Buspirone 10 mg twice daily increasing to 15 mg in addition to fluoxetine, or
2. Amantadine 50mg once daily increasing to 50mg twice daily in addition to fluoxetine,
or
3. Placebo twice daily, in addition to fluoxetine
Outcomes Interviewer Rating of Sexual Function,
Participant-rated VAS for sexual function,
Clinician-rated global impression and participant-rated global impression,
HAM-D, Beck Depression Inventory, State-Trait Anxiety Inventory
Notes Trial performed in USA.
Buspirone is a 5HT-1A agonist
Amantadine is thought to increase dopamine availability
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details of sequence generation method
provided
Allocation concealment (selection bias) Unclear risk -
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’Patients and efficacy raters were blinded to
treatment assignment and to the criteria for
study entry and dose adjustments’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’Patients and efficacy raters were blinded to
treatment assignment and to the criteria for
study entry and dose adjustments’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Patients and efficacy raters were blinded to
treatment assignment and to the criteria for
study entry and dose adjustments
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data analysed from 57 out of total of 61
randomised
Selective reporting (reporting bias) Unclear risk -
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Michelson 2002
Methods Double-blind, parallel-arm. multicentred trial (12 centres), 6-week treatment period
Participants 148 women randomised.
Inclusion criteria: stable dose of fluoxetine leading to reduced lubrication, or orgasmic
dysfunction, or both; condition for which fluoxetine prescribed responded satisfactorily
Interventions 1. Mirtazapine 15 mg once daily increasing to 30 mg in addition to fluoxetine, or
2. Yohimbine 5.4 mg once daily increasing to 10.8 mg in addition to fluoxetine, or
3. Olanzapine 2.5 mg once daily increasing to 5 mg in addition to fluoxetine, or
4. Placebo, in addition to fluoxetine.
Medications taken daily 1-2 h before sexual activity
Outcomes Participant-assessment of sexual function, Daily diary VAS, Kinsey Ratings of Sexual
Function - computer-assisted structured interview
Notes Trial performed in USA.
Mirtazapine is a 5HT2 and alpha-2 adrenergic antagonist.
Yohimbine is an alpha-2 adrenergic antagonist.
Olanzapine is a 5HT2 antagonist (and dopamine antagonist)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No data on sequence generation method
provided
Allocation concealment (selection bias) Unclear risk -
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’Double blind’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’Double blind’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ’Double blind’
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk -
Selective reporting (reporting bias) Unclear risk -
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Nelson 2001
Methods Double-blind, cross-over design, 6-week duration
Participants 20 adults randomised (2 men, 18 women).
Inclusion criteria: sexual dysfunction began whilst taking SSRI; HAM-D score < 10
Interventions 1. Granisetron 1-2 mg, as required, in addition to SSRI, or
2. Placebo, in addition to SSRI.
Medication taken 1-2 h prior to sexual activity
Outcomes SSES, HAM-D
Notes Trial performed in USA.
Granisetron is a 5-HT3 antagonist
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details of sequence generation method
provided
Allocation concealment (selection bias) Unclear risk -
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’Double blind’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’Double blind’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ’Double blind’
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk -
Selective reporting (reporting bias) Unclear risk -
Nurnberg 2008
Methods Double-blind, randomised, placebo-controlled, multicentred trial, 8-week duration
Participants 98 women randomised, aged 18-50 years.
Includsion criteria: substance-induced sexual dysfunction to DSM-IV criteria; major de-
pressive disorder, in remission; taking antidepressant with serotonin reuptake inhibition
action for at least 8 weeks; persistent sexual dysfunction for at least 4 weeks
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Nurnberg 2008 (Continued)
Interventions 1. Sildenafil, flexible dose between 50 mg and 100mg, or
2. Placebo
Medication taken 1-2 h before sexual activity, not more than once daily
Outcomes CGI scale, Sexual Function Questionnaire, ASEX, University of New Mexico Sexual
Function Inventory - female version
Notes Trial performed in USA - 7 centres
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Used an unrestricted computer-generated
randomisation schedule using SPSS version
10, restriction to this randomisation was
that the groups had to be of equal size
Allocation concealment (selection bias) Low risk The randomisation schedule was given to
an independent pharmacy
Medications were sealed in sequentially-
numbered identical containers according
to allocation sequence
Blinding (performance bias and detection
bias)
All outcomes
Low risk All study personnel and participants were
blinded to treatment assignment for the du-
ration of the study
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All study personnel and participants were
blinded to treatment assignment for the du-
ration of the study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All study personnel and participants were
blinded to treatment assignment for the du-
ration of the study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk -
Selective reporting (reporting bias) Unclear risk -
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Nurnberg 2002
Methods Multicentred, double-blind, placebo-controlled trial, 8-week duration, followed by sin-
gle-blind, open-label 8-week extension
Participants 150 women.
Inclusion criteria: major depressive disorder in remission; serotonergic reuptake in-
hibitor-associated female sexual dysfunction; no pre-existing sexual dysfunction; 38
weeks stable dose SRI; HAM-D score < 10; significant sexual dysfunction by CGI-SF
Interventions 1. Sildenafil (50-100 mg flexible dose), or
2. Matching placebo
Outcomes CGI-SF, HAM-D
Notes Limited information, no outcome data available from end of randomised phase
Outcomes reported after further open-label sildenafil treatment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk -
Allocation concealment (selection bias) Unclear risk -
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk -
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk -
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk -
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk -
Selective reporting (reporting bias) Unclear risk -
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Nurnberg 2003
Methods Multicentred (3 centres), double-blind, parallel-arm trial, 6-week duration
Participants 90 men (aged 18-55 years) randomised.
Inclusion criteria: taking stable dose of an SSRI with substance-induced sexual dysfunc-
tion for more than 4 weeks; DSM-IV major depressive disorder in remission; HAM-A
score < 11; HAM-D score < 11
Interventions 1. Sildenafil 50 mg, as required, increasing to 100 mg, as required, in addition to SSRI,
or
2. Placebo in addition to SSRI
Outcomes IIEF, ASEX, MGH-SFQ, HAM-D
Notes Trial performed in USA - 3 centres
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Developed an unrestricted computer-gen-
erated randomisation schedule using SPSS
version 10
Allocation concealment (selection bias) Low risk Randomisation schedule was given to an
independent pharmacy. Medications were
sealed in sequentially-numbered, identical
containers according to allocation sequence
Blinding (performance bias and detection
bias)
All outcomes
Low risk All study personnel and patents were
blinded to treatment for the duration of the
study
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All study personnel and patents were
blinded to treatment for the duration of the
study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All study personnel and patents were
blinded to treatment for the duration of the
study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk -
Selective reporting (reporting bias) Unclear risk -
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Safarinejad 2010
Methods Parallel-group design, 12-week randomised phase
Participants 234 men (aged 25-50 years).
Inclusion criteria: major depressive disorder currently in remission; stable dose of SSRI
for at least 6 months; new sexual dysfunction for at least 4 weeks
Interventions 1. Bupropion SR 150 mg twice daily, or
2. Placebo
Outcomes CGI-SF, IIEF, ASEX, Erectile Dysfunction Inventory of Treatment Satisfaction (patient
and partner versions), HAM-D and HAM-A
Notes Trial performed in Iran
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation number for assignment to
treatment groupwas determined using ran-
dom permuted blocks
Allocation concealment (selection bias) Unclear risk -
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’Double blind’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’Double blind’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigator was not involved in the recruit-
ment procedure and did not know the ran-
domisation list. Seals were broken after the
trial
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Unclear risk -
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Safarinejad 2011
Methods Parallel-group design, 12 weeks of randomised treatment after 1 week placebo run-in
Participants 218 women (aged 25-45).
Inclusion criteria: SSRI-induced sexual dysfunction; first episode of major depressive
disorder in remission
Interventions 1. Bupropion SR 150 mg twice daily, or
2. Placebo
Outcomes CGI-SF, Female Sexual Function Index, HAM-D
Notes Trial performed in Iran
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated schedule
Allocation concealment (selection bias) Unclear risk -
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk -
Selective reporting (reporting bias) Unclear risk -
Wheatley 2004
Methods Triple-blind, parallel-arm design. 12 weeks of treatment after 1 week run-in without
treatment
Participants 24 adults randomised (14 men, 10 women), aged 18-65 years.
Inclusion criteria: taking antidepressant for at least 2 weeks and experiencing sexual
problems as a consequence
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Wheatley 2004 (Continued)
Interventions 1. Ginkgo biloba (LI-156) 240 mg daily, or
2. Placebo daily
Outcomes Changes in sexual dysfunction scale, ASEX, University of Mexico Sexual Function In-
ventory
Notes Trial performed in the UK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated schedule
Allocation concealment (selection bias) Unclear risk -
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Allocation blinded to participant, investi-
gator and statistician
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Allocation blinded to participant, investi-
gator and statistician
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk -
Incomplete outcome data (attrition bias)
All outcomes
Low risk -
Selective reporting (reporting bias) Unclear risk -
Abbreviations
< = less than
> = more than
ASEX = Arizona Sexual Experiences scale
BISF-W = Brief Index of Sexual Functioning for Women
CGI = Clinical Global Impression scale
CGI-SF = Clinical Global Impression scale for Sexual Function
CSFQ = Changes in Sexual Functioning Questionnaire
DSM-III-R = Diagnostic and Statistical Manual of American Psychiatric Association, third edition, revised
DSM-IV = Diagnostic and Statistical Manual of American Psychiatric Association, fourth edition
FSFSQ = Feiger Sexual Function and Satisfaction Questionnaire
h = hour(s)
HAM-A = Hamilton rating scale for anxiety
HAM-D = Hamilton rating scale for depression
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IIEF = International Index of Erectile Function
MGH-SFQ = Massachusetts General Hospital-Sexual Function Questionnaire
MINI = Mini-Mental State Examination
SEP diary = Sexual Encounter Profile diary
SR = sustained release
SRI = Serotonin Reuptake Inhibitor
SSES = Sexual Side Effects Scale
SSRI = Selective Serotonin Reuptake Inhibitor
VAS = Visual Analogue Scale
UKU = Udvalg fur Kliniske Undersogelser
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aizenberg 2003 Non-randomised design
Amiaz 2011 Not established as antidepressant-induced sexual dysfunction: depressed men, also hypogonadal (low or low-
normal testosterone levels)
Ashton 1998 Non-randomised design
Berk 2000 Non-randomised design
Cohen 1999 Non-randomised design
Dording 2012 Not established as antidepressant-induced sexual dysfunction: changes in sexual dysfunction ratings during
treatment for resistant depression
Gelenberg 2000 Non-randomised design
Landen 1999 Not established as antidepressant-induced sexual dysfunction: changes in sexual dysfunction ratings during
treatment for resistant depression
Mansoori 2011 Not a study of sexual dysfunction effects (safety evaluation)
Moore 2002 Review article
Nurnberg 2001 Pooled analysis of subgroup data from multiple individual studies; participants taking antidepressant medica-
tion, but not established as antidepressant-induced sexual dysfunction
Ozmenler 2008 Non-randomised design
Pae 2009 Not established as antidepressant-induced sexual dysfunction: changes in sexual dysfunction ratings during
treatment for resistant depression
Salerian 2000 Non-randomised design
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(Continued)
Salerian 2002 Non-randomised design
Segraves 2007 Pooled analysis of subgroup data from multiple individual studies; participants taking antidepressant medica-
tion, but not established as antidepressant-induced sexual dysfunction
Tignol 2004 Not established as antidepressant-induced sexual dysfunction: persistent erectile dysfunction after depression
was brought into remission with or without antidepressant medication
Walker 1993 Non-randomised design
Worthington 2002 Non-randomised design
Characteristics of studies awaiting assessment [ordered by study ID]
Croft 2012
Methods Randomized allocation
Participants Women, aged 18-50 years.
Inclusion criteria: mild or remitted depressive disorder; SSRI or SNRI; decreased sexual desire and distress present
for at least 4 weeks
Interventions 1. Flibanserin, or
2. Placebo
Outcomes
Notes
Kashani 2013
Methods Random allocation
Participants 38 women.
Inclusion criteria: major depression; stabilized on fluoxetine 40 mg/day for a minimum of 6 weeks; had experienced
subjective feeling of sexual dysfunction
Interventions 1. Saffron (30 mg/daily), for 4 weeks, or
2. Placebo for 4 weeks
Outcomes FSFI
Notes
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MGH 2013
Methods Randomised allocation
Participants Women, aged 45-65 years.
Inclusion criteria: post-menopause; persistent depression despite SSRI treatment
Interventions 1. Testosterone cream, or
2. Placebo
Outcomes
Notes Study title ’Testosterone Antidepressant Augmentation in Women’
Modabbernia 2012
Methods Randomised, double-blind, placebo-controlled study
Participants 36 men
Inclusion criteria: major depressive disorder; depressive symptoms stabilized on fluoxetine; subjective complaints of
sexual impairment
Interventions 1. Saffron (15 mg twice per day) for 4 weeks, or
2. Placebo for 4 weeks
Outcomes IIEF scale
Notes
Abbreviations
IIEF = International Index of Erectile Function
SSRI = Selective Serotonin Reuptake Inhibitor
Characteristics of ongoing studies [ordered by study ID]
Chiang 2010
Trial name or title Trazodone for SSRI-SD in Civilian Administration Division of Beitou Armed Forces Hospital
Methods Randomized, placebo-control. cross-over design, 6-week duration
Participants Inclusion criteria: participants 20-65 years of age; receiving SSRI treatment for > 4 weeks; minimal dose of
fluoxetine, paroxetine, and citalopram 20 mg/day; minimal dose of fluvoxamine and sertraline 50 mg/day;
and minimal dose of escitalopram 10 mg/day; developing sexual dysfunction based on the definition of ASEX
Chinese version
Interventions 1. Trazodone 50 mg/day titrated to 100 mg/day over 1 week, then maintained, or
2. Placebo
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Chiang 2010 (Continued)
Outcomes Primary outcomes: differences between trazodone and placebo in the ASEX Chinese version at the end of
week 6
Secondary outcomes assessed include: difference between trazodone and placebo in the CGI scale, 10-point
VAS,HAM-D, andHAM-A at the end of week 6. Relationships between 5-HT2Apolymorphism and changes
in ASEX Chinese version also evaluated
Starting date 2010
Contact information Kuo-Tung Chiang, MD
Notes
Dording 2010
Trial name or title A double-blind, placebo-controlled study of maca root for the treatment of antidepressant-induced sexual
dysfunction in women
Methods Randomized. 12-week duration
Participants Women, 18-80 years
Interventions 1. Maca root 3 g/day, or
2. Placebo
Outcomes Decrease in baseline ASEX and MGH-Sexual Dysfunction scores
Starting date 2007
Contact information Christina Dording, MD, Massachussetts General Hospital
Notes
Hellerstein 2008
Trial name or title Treatment of sexual dysfunction secondary to antidepressant pharmacotherapy: a double-blind comparison
of Requip (Ropinirole) vs placebo in patients taking SSRI antidepressants
Methods Randomized, cross-over trial, 6- week duration
Participants Inclusion criteria: male or female outpatients, 18-65 years old; currently taking fluoxetine, sertraline, paroxe-
tine, citalopram, or escitalopram at a stable dosage within the ranges specified for 1 month or longer; required
dosage range: (Prozac (fluoxetine) 20-80 mg/day; Celexa (citalopram) 20-60 mg/day; Lexapro (escitalopram)
10-30 mg/day; Zoloft (sertraline) 50-200 mg/day; Paxil (paroxetine) 20-60 mg/day; Paxil CR (paroxetine
CR) 25-75 mg/day; currently responding to SSRI antidepressant treatment, as indicated by a score of 15 or
less on the HAM-D 24-item at screening and baseline, and (b) CGI-Severity score of 2 or less at baseline;
meets DSM-IV criteria for Substance-Induced Sexual Dysfunction, with impairment of desire, arousal, or
orgasm; currently involved in an intimate relationship that includes sexual contact; agree to use double-barrier
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Hellerstein 2008 (Continued)
contraception during sexual intercourse during the course of the study (women only); agree to let the study
team contact the physician who prescribed the SSRI medication to inform him/her of patient’s participation
in the current study
Interventions 1. Ropinirole 1 mg extended release formulation given once/day to a maximum of 4/day
2. placebo
Outcomes Primary outcomes: IIEF, SFSQ
Secondary outcomes: HAM-D 17-items, GAFS, CGI, CGI-SF
Starting date 2006
Contact information David J Hellerstein, MD St. Luke’s Roosevelt Hospital Center and NY State Psychiatric Institute
Notes
Meston 2008
Trial name or title Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction
Methods Parallel-group design
Participants 36 women (age 18-65 years).
Inclusion criteria: stabilised on antidepressant medication and free of a current Axis I disorder
Interventions 1. Ginkgo biloba extract 200 mg for 8 weeks, or
2. Placebo for 8 weeks
Outcomes Daily participant diary, participant-rating scales, blind independent evaluator ratings, vaginal photoplethys-
mography
Starting date June 2002
Contact information Cindy Meston, University of Texas at Austin
Notes Outcomes for those with antidepressant-associated sexual dysfunction not yet published
Takeda 2011
Trial name or title A randomised, double-blind, parallel-group, active-controlled, flexible-dose study evaluating the effect of
Lu AA21004 vs escitalopram on sexual functioning in adults with well-treated major depressive disorder
experiencing selective serotonin reuptake inhibitor-induced sexual dysfunction
Methods Randomised; parallel-group design; blinding applied to subjects, caregivers, investigators, outcomes assessors,
8-week treatment duration
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Takeda 2011 (Continued)
Participants Estimated enrolment: 440, aged 18-55 years; male and female participants
Inclusion criteria: treated for last 8 weeks, or more, with SSRI monotherapy (only citalopram, paroxetine,
or sertraline allowed) prescribed to treat a major depressive episode, according to the DSM-IV-TR criteria;
depression currently stable; subject has a CGI Scale-Severity of Illness Scale (CGI-S) score of ≤ 3; currently
experiencing treatment-emergent sexual dysfunction (defined as a CSFQ-14 total score ≤ 41 for women
and ≤ 47 for men); considered to be attributable to the current SSRI monotherapy; suitable for a switch in
medication
Interventions 1. Lu AA21004 up to 20 mg daily, or
2. Escitalopram up to 20 mg daily
Outcomes Primary outcome: change from baseline in the CSFQ-14 Total Score
Starting date June 2011
Contact information Contact: Takeda Study Registration Call Center
Notes 62 study locations in USA and Canada
Lu AA21004 is also known as vortioxetine
Van Rooiji 2010
Trial name or title Lybrido(s) and SSRIs@Home: a double-blind, randomised, cross-over, placebo-controlled study to investigate
the subjective and physiological efficacy and safety of Lybrido and Lybridos in the domestic setting in healthy
women with female sexual dysfunction in combination with SSRI use. - @HOME
Methods Cross-over design in which a placebo regime (duration 4 weeks), the Lybrido regime (duration 4 weeks), and
the Lybridos regime (duration 4 weeks) are separated by a 1- to 4-week washout period
Participants Target sample size: 40
Inclusion criteria: women21-70 years oldwith hypoactive sexual desire disorder (comorbiditywith other sexual
dysfunctions e.g. Female Sexual Arousal Disorder (FSAD) allowed) or SSRI-induced sexual dysfunctioning,
or both; at least 3 months use of an SSRI; SSRI must be on a stable dose for at least 6 weeks
Interventions 1. Lybrido [combination testosterone and sildenafil], or
2. Lybridos [combination testosterone and buspirone], or
3. Placebo
Outcomes Unclear
Starting date January 2010
Contact information Emotional Brain bv,
Louis Armstrongweg 78
1311 RL
Almere
The Netherlands
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Van Rooiji 2010 (Continued)
Notes
Abbreviations
≤ = less than or equal to
> = more than
ASEX = Arizona Sexual Experiences scale
CGI = Clinical Global Impression scale
CGI-SF = Clinical Global Impression scale for Sexual Function
CSFQ = Changes in Sexual Functioning Questionnaire
DSM-IV = Diagnostic and Statistical Manual of American Psychiatric Association, fourth edition
DSM-IV-TR = Diagnostic and Statistical Manual of American Psychiatric Association, fourth edition, text revision
FSFI = Female sSexual Function Index
GAFS = Global Assessment of Functioning Scale
HAM-D = Hamilton rating scale for depression
IIEF = International Index of Erectile Function
MGH = Massachusetts General Hospital
SFSQ = Sexual Function Satisfaction Questionnaire
SNRI = Serotonin-Norepinephrine Reuptake Inhibitor
SSRI = Selective Serotonin Reuptake Inhibitor
VAS = Visual Analogue Scale
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D A T A A N D A N A L Y S E S
Comparison 1. Sildenafil vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Endpoint International Index of
Erectile Function (IIEF) scores
3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Total score 2 112 Mean Difference (IV, Fixed, 95% CI) 19.36 [15.00, 23.72]
1.2 Erectile function
(questions 1-5,15)
1 89 Mean Difference (IV, Fixed, 95% CI) 10.0 [7.39, 12.61]
1.3 Question 3: ability to
achieve erection
2 231 Mean Difference (IV, Fixed, 95% CI) 1.04 [0.65, 1.44]
1.4 Question 4: ability to
maintain erection
2 231 Mean Difference (IV, Fixed, 95% CI) 1.18 [0.78, 1.59]
1.5 Intercourse satisfaction
(questions 6, 7, 8)
1 89 Mean Difference (IV, Fixed, 95% CI) 3.50 [2.48, 4.52]
1.6 Orgasmic function
(questions 9, 10)
1 89 Mean Difference (IV, Fixed, 95% CI) 2.5 [1.36, 3.64]
1.7 Sexual desire (questions
11, 12)
1 89 Mean Difference (IV, Fixed, 95% CI) 0.5 [-0.38, 1.38]
1.8 Overall satisfaction
(questions 13,14)
1 89 Mean Difference (IV, Fixed, 95% CI) 1.80 [0.86, 2.74]
2 Endpoint Erectile Dysfunction
Inventory of Treatment
Satisfaction (EDITS) scores
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Total score 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Endpoint Clinical Global
Impression - Sexual Function
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4 Clinical Global Impression
-Sexual Function not
”much/very much improved”
by endpoint
2 187 Risk Ratio (M-H, Fixed, 95% CI) 0.44 [0.33, 0.58]
4.1 Males 1 89 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.34, 0.66]
4.2 Females 1 98 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.24, 0.62]
5 Endpoint Arizona Sexual
Experience Scale (ASEX) total
scores
3 210 Mean Difference (IV, Fixed, 95% CI) -2.65 [-3.86, -1.44]
5.1 Males 2 112 Mean Difference (IV, Fixed, 95% CI) -4.62 [-6.29, -2.95]
5.2 Females 1 98 Mean Difference (IV, Fixed, 95% CI) -0.5 [-2.24, 1.24]
6 Males: endpoint Arizona Sexual
Experience Scale scores
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
6.1 Total score 2 112 Mean Difference (IV, Fixed, 95% CI) -4.62 [-6.29, -2.95]
6.2 Sexual desire 1 89 Mean Difference (IV, Fixed, 95% CI) -0.60 [-1.08, -0.12]
6.3 Arousal 1 89 Mean Difference (IV, Fixed, 95% CI) -0.60 [-1.06, -0.14]
6.4 Erectile function 1 89 Mean Difference (IV, Fixed, 95% CI) -1.20 [-1.66, -0.74]
6.5 Orgasm (ability) 1 89 Mean Difference (IV, Fixed, 95% CI) -1.40 [-1.90, -0.90]
6.6 Orgasm (satisfaction) 1 89 Mean Difference (IV, Fixed, 95% CI) -1.0 [-1.58, -0.42]
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7 Endpoint MGH-Sexual
Functioning Questionnaire
scores
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 Total score 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 Sexual desire 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 Arousal 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.4 Erectile function 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.5 Orgasm (ability) 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.6 Overall satisfaction 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Sexual dysfunction defined by
Arizona Sexual Experience
Scale at trial endpoint
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
9 Dropouts 4 353 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.41, 1.14]
10 Endpoint Hamilton Rating
Scale for Depression score
2 187 Mean Difference (IV, Fixed, 95% CI) -0.94 [-1.94, 0.07]
11 Loss of remission: Hamilton
Rating Scale for Depression
score > 9
3 330 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.04, 3.09]
12 Global Efficacy Questionnaire
(questions 1 & 2)
1 284 Risk Ratio (M-H, Fixed, 95% CI) 2.53 [1.90, 3.35]
12.1 Improvement in
erections
1 142 Risk Ratio (M-H, Fixed, 95% CI) 2.5 [1.67, 3.73]
12.2 Improvement in ability
to have sexual intercourse
1 142 Risk Ratio (M-H, Fixed, 95% CI) 2.55 [1.71, 3.80]
13 Global efficacy questionnaire
(question 3)
1 129 Mean Difference (IV, Fixed, 95% CI) 1.2 [0.65, 1.75]
13.1 Question 3: Frequency
of erection that allowed
satisfactory sexual intercourse
1 129 Mean Difference (IV, Fixed, 95% CI) 1.2 [0.65, 1.75]
14 Endpoint Sexual Function
Questionnaire (SFQ)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
14.1 Desire 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14.2 Arousal-sensation 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14.3 Arousal-lubrication 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14.4 Orgasm 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14.5 Enjoyment 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14.6 Pain 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14.7 Partner 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
15 UNM Sexual Function
Inventory
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
15.1 Total score 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.2 Desire 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.3 Sexual arousal 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.4 Lubrication 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.5 Ability to reach orgasm 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.6 Overall satisfaction 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
16 Females: endpoint Arizona
Sexual Experience Scale scores
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
16.1 Total score 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
16.2 Sexual desire 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
16.3 Arousal 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
16.4 Orgasm (ability) 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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16.5 Orgasm (satisfaction) 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
16.6 Lubrication 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. Tadalafil vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Global Assessment Questions 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Has the treatment you
have been taking improved
your erectile function?
1 50 Risk Ratio (M-H, Fixed, 95% CI) 11.5 [3.03, 43.67]
1.2 Has the treatment
improved your ability to engage
in sexual activity?
1 50 Risk Ratio (M-H, Fixed, 95% CI) 11.5 [3.03, 43.67]
2 Endpoint Sexual Encounter
Profile (SEP)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Question 2: Were you
able to insert your penis into
your partner’s vagina?
1 50 Risk Ratio (M-H, Fixed, 95% CI) 2.33 [0.68, 8.01]
2.2 Question 3: Did your
erection last long enough
for you to have successful
intercourse?
1 50 Risk Ratio (M-H, Fixed, 95% CI) 6.0 [0.78, 46.29]
2.3 Question 4: Were you
satisfied with the hardness of
your erection?
1 50 Risk Ratio (M-H, Fixed, 95% CI) 6.0 [0.78, 46.29]
2.4 Question 5: Were you
satisfied overall with this sexual
experience?
1 50 Risk Ratio (M-H, Fixed, 95% CI) 6.0 [0.78, 46.29]
3 Dropouts 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Overall 1 54 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.04, 3.24]
3.2 Lack of efficacy 1 54 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.04, 3.24]
3.3 Adverse effects 1 54 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 3. Bupropion vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Endpoint scale total scores 3 482 Std. Mean Difference (IV, Fixed, 95% CI) 1.60 [1.40, 1.81]
1.1 International Index of
Erectile Function (IIEF)
1 227 Std. Mean Difference (IV, Fixed, 95% CI) 1.76 [1.45, 2.07]
1.2 Female Sexual Function
Index (FSFI)
1 213 Std. Mean Difference (IV, Fixed, 95% CI) 1.73 [1.41, 2.05]
65Strategies for managing sexual dysfunction induced by antidepressant medication (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1.3 Changes in Sexual
Functioning Questionnaire
(CSFQ)
1 42 Std. Mean Difference (IV, Fixed, 95% CI) 0.50 [-0.11, 1.12]
2 Response (as defined by study) 3 284 Risk Ratio (M-H, Fixed, 95% CI) 31.77 [10.10, 99.89]
2.1 50% reduction Arizona
Sexual Experiences Scale
(ASEX)
2 71 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.09, 4.41]
2.2 Clinical Global
Impression (CGI-SF) 2-point
improvement
1 213 Risk Ratio (M-H, Fixed, 95% CI) 186.73 [11.74,
2969.23]
3 Endpoint International Index of
Erectile Function (IIEF)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Total score 1 227 Mean Difference (IV, Fixed, 95% CI) 20.10 [17.14, 23.06]
3.2 Erectile function 1 227 Mean Difference (IV, Fixed, 95% CI) 9.30 [8.18, 10.42]
3.3 Orgasmic function 1 227 Mean Difference (IV, Fixed, 95% CI) 2.70 [2.15, 3.25]
3.4 Sexual desire 1 227 Mean Difference (IV, Fixed, 95% CI) 2.10 [1.76, 2.44]
3.5 Intercourse satisfaction 1 227 Mean Difference (IV, Fixed, 95% CI) 3.6 [3.00, 4.20]
3.6 Overall satisfaction 1 227 Mean Difference (IV, Fixed, 95% CI) 2.60 [1.99, 3.21]
4 Endpoint Female Sexual
Function Index score
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 Total score 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Desire 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Arousal 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.4 Lubrication 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.5 Orgasm 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.6 Satisfaction 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.7 Pain 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Endpoint Changes in Sexual
Functioning Questionnaire
score
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 Total score 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Desire/interest 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 Desire/frequency 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.4 Arousal/excitement 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.5 Completion/orgasm 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Dropouts 5 579 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.67, 1.72]
7 Endpoint Hamilton Rating Scale
for Depression score
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8 Endpoint Clinical Global
Impression (CGI - SF)
2 440 Mean Difference (IV, Fixed, 95% CI) -1.74 [-1.87, -1.61]
8.1 Male 1 227 Mean Difference (IV, Fixed, 95% CI) -1.5 [-1.80, -1.20]
8.2 Female 1 213 Mean Difference (IV, Fixed, 95% CI) -1.80 [-1.95, -1.65]
9 Endpoint ASEX 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9.1 Total score 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.2 Erectile function 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.3 Sexual desire 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.4 Arousal 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.5 Ability to reach orgasm 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.6 Satisfaction with orgasm 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Endpoint EDITS (participant) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
10.1 Total score 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 Overall satisfaction 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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10.3 Expectations 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.4 Likelihood of continuing 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.5 Confidence 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.6 Partner satisfaction 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.7 Partner desire to
continue treatment
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.8 Naturalness of achieving
erection
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.9 Naturalness of erection
hardness
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.10 Quickness of achieving
erection
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.11 Duration that erection
lasts
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.12 Ease of use 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Endpoint EDITS (partner) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
11.1 Total score 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.2 Overall satisfaction 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.3 Expectations 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.4 Sexual desirability 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.5 Participant’s feelings
about continuing treatment
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.6 Duration that erection
lasts
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 4. Nefazodone vs sertraline
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Re-emergence of
antidepressant-induced sexual
dysfunction (physician rated)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Week 1 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Endpoint 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Overall degree of sexual
satisfaction (participant rated)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Baseline 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Week 8 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Last rating recorded 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Dropouts 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Overall 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Attributed to adverse
effects
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Hamilton Rating Scale for
Depression score
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 Baseline 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Week 8 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 5. Ginkgo biloba vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Endpoint sexual function ratings
(investigator questionnaire)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Sexual desire 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Overall sexual function 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Erection maintenance
time
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 Orgasm frequency 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.5 Satisfaction to orgasm 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Sexual Dysfunction Scale
(investigator developed)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Baseline 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Week 12 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Dropouts 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 6. Granisetron vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change from baseline on Sexual
Side Effects Scale (SSES) total
score
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Endpoint Feiger Sexual Function
and Satisfaction Questionnaire
score
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Total score 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Item 1 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Item 2 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.4 Item 3 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.5 Item 4 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.6 Item 5 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.7 Item 6 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Endpoint Arizona Sexual
Experience Scale (ASEX) score
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Total score 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Sexual desire 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Arousal 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.4 Lubrication 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.5 Orgasm (ability) 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.6 Orgasm (satisfaction) 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Dropouts 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Recurrence of mood symptoms 1 43 Risk Ratio (M-H, Fixed, 95% CI) 2.87 [0.12, 66.75]
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Comparison 7. VML-670 vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Absence of sexual dysfunction at
end point
1 266 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [0.86, 1.77]
2 ’Improved’ or ’much improved’
on Clinical Global Impression
1 266 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [0.71, 2.17]
3 Change in Arizona Sexual
Experiences Scale (ASEX) item
scores
1 1264 Mean Difference (IV, Fixed, 95% CI) -0.07 [-0.19, 0.05]
3.1 How strong is your sexual
drive?
1 255 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.36, 0.16]
3.2 How easily are you
sexually aroused?
1 253 Mean Difference (IV, Fixed, 95% CI) -0.20 [-0.47, 0.07]
3.3 Females: how easily does
your vagina become moist or
wet?
1 180 Mean Difference (IV, Fixed, 95% CI) 0.10 [-0.22, 0.42]
3.4 Males: can you easily get
and keep an erection?
1 72 Mean Difference (IV, Fixed, 95% CI) -0.4 [-0.80, 0.00]
3.5 How easily can you reach
orgasm?
1 252 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.28, 0.28]
3.6 Are your orgasms
satisfying?
1 252 Mean Difference (IV, Fixed, 95% CI) 0.10 [-0.22, 0.42]
4 Dropouts 1 532 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [0.73, 1.93]
4.1 Total 1 266 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.56, 1.68]
4.2 Attributed to adverse
effects
1 266 Risk Ratio (M-H, Fixed, 95% CI) 2.32 [0.75, 7.21]
Comparison 8. Buspirone vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in patient-rated visual
analogue scales
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Overall function (total of
interest, lubrication, orgasm,
pleasure)
1 39 Mean Difference (IV, Fixed, 95% CI) 3.10 [-38.33, 44.53]
1.2 Mood 1 39 Mean Difference (IV, Fixed, 95% CI) 0.80 [-7.61, 9.21]
1.3 Energy 1 39 Mean Difference (IV, Fixed, 95% CI) 5.30 [-3.88, 14.48]
1.4 Interest/desire 1 39 Mean Difference (IV, Fixed, 95% CI) 2.70 [-7.99, 13.39]
1.5 Lubrication 1 39 Mean Difference (IV, Fixed, 95% CI) 9.90 [-3.65, 23.45]
1.6 Orgasm 1 39 Mean Difference (IV, Fixed, 95% CI) -6.3 [-19.98, 7.38]
1.7 Pleasure 1 39 Mean Difference (IV, Fixed, 95% CI) -3.20 [-15.53, 9.13]
1.8 Discomfort 1 39 Mean Difference (IV, Fixed, 95% CI) 7.00 [-3.15, 17.15]
2 Dropouts 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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Comparison 9. Bethanecol vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Visual analogue scale of orgasmic
function - best score achieved
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 10. Olanzapine vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in patient rated
assessment of sexual function
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Overall satisfaction 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Sexual interest 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Psychological arousal 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 Lubrication 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.5 Orgasm 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Change in diary ratings (visual
analogue scales)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Overall sexual function 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Mood 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Energy 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.4 Sexual interest 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.5 Psychological arousal 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.6 Physical arousal 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.7 Orgasm 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.8 Pleasure/enjoyment 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.9 Discomfort 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Dropouts due to adverse effects 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 11. Mirtazapine vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in patient rated
assessment of sexual function
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Overall satisfaction 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Sexual interest 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Psychological arousal 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 Lubrication 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.5 Orgasm 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
70Strategies for managing sexual dysfunction induced by antidepressant medication (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2 Change in diary ratings (visual
analogue scales)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Overall sexual function 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Mood 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Energy 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.4 Sexual interest 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.5 Psychological arousal 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.6 Physical arousal 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.7 Orgasm 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.8 Pleasure/enjoyment 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.9 Discomfort 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Endpoint modified Kinsey
Structured Interview
1 75 Mean Difference (IV, Fixed, 95% CI) 0.60 [0.19, 1.01]
3.1 Sexual satisfaction 1 75 Mean Difference (IV, Fixed, 95% CI) 0.60 [0.19, 1.01]
4 Dropouts 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Attributed to adverse
effects
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 12. Yohimbine vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in patient rated
assessment of sexual function
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Overall satisfaction 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Sexual interest 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Psychological arousal 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 Lubrication 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.5 Orgasm 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Change in diary ratings (visual
analogue scales)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Overall sexual function 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Mood 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Energy 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.4 Sexual interest 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.5 Psychological arousal 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.6 Physical arousal 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.7 Orgasm 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.8 Pleasure/enjoyment 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.9 Discomfort 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Dropouts 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Attributed to adverse
effects
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 13. Amantadine vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in patient-rated visual
analogue scales
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Overall function (total of
interest, lubrication, orgasm,
pleasure)
1 38 Mean Difference (IV, Fixed, 95% CI) 13.0 [-29.02, 55.02]
1.2 Mood 1 38 Mean Difference (IV, Fixed, 95% CI) 8.1 [1.23, 14.97]
1.3 Energy 1 38 Mean Difference (IV, Fixed, 95% CI) 12.7 [5.30, 20.10]
1.4 Interest/desire 1 38 Mean Difference (IV, Fixed, 95% CI) 0.90 [-7.96, 9.76]
1.5 Lubrication 1 38 Mean Difference (IV, Fixed, 95% CI) 7.90 [-5.74, 21.54]
1.6 Orgasm 1 38 Mean Difference (IV, Fixed, 95% CI) 2.50 [-11.91, 16.91]
1.7 Pleasure 1 38 Mean Difference (IV, Fixed, 95% CI) 1.70 [-11.28, 14.68]
1.8 Discomfort 1 38 Mean Difference (IV, Fixed, 95% CI) 1.30 [-11.25, 13.85]
2 Dropouts 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 14. ephedrine vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Endpoint Brief Index of Sexual
Functioning for Women
(BISF-W)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Sexual desire 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Sexual arousability 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Lack of vaginal lubrication 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 Orgasm ability 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.5 Orgasm intensity/pleasure 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.6 Sexual dissatisfaction 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 15. Maca root: high vs low dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Endpoint Arizona Sexual
Experiences Scale (ASEX) score
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Total score 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Question 1: Sexual desire 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Endpoint MGH-SFQ 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Total score 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Item a: Sexual desire 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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3 Dropouts 1 20 Risk Ratio (M-H, Fixed, 95% CI) 1.5 [0.60, 3.74]
4 Endpoint ratings of psychiatric
symptoms
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 Hamilton Depression
Rating Scale
1 16 Mean Difference (IV, Fixed, 95% CI) -2.5 [-7.98, 2.98]
4.2 Hamilton Anxiety Rating
Scale
1 16 Mean Difference (IV, Fixed, 95% CI) -0.40 [-3.15, 2.35]
Analysis 1.1. Comparison 1 Sildenafil vs placebo, Outcome 1 Endpoint International Index of Erectile
Function (IIEF) scores.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 1 Sildenafil vs placebo
Outcome: 1 Endpoint International Index of Erectile Function (IIEF) scores
Study or subgroup Sildenafil Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Total score
Ginsberg 2001 12 62.6 (14) 11 44.2 (15.7) 12.8 % 18.40 [ 6.20, 30.60 ]
Nurnberg 2003 44 60.4 (10.3) 45 40.9 (12.1) 87.2 % 19.50 [ 14.84, 24.16 ]
Subtotal (95% CI) 56 56 100.0 % 19.36 [ 15.00, 23.72 ]
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 8.71 (P < 0.00001)
2 Erectile function (questions 1-5,15)
Nurnberg 2003 44 27.1 (3.7) 45 17.1 (8.1) 100.0 % 10.00 [ 7.39, 12.61 ]
Subtotal (95% CI) 44 45 100.0 % 10.00 [ 7.39, 12.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.52 (P < 0.00001)
3 Question 3: ability to achieve erection
Fava 2006 71 3.9 (1.69) 71 3.1 (1.69) 51.2 % 0.80 [ 0.24, 1.36 ]
Nurnberg 2003 44 4.4 (1.1) 45 3.1 (1.6) 48.8 % 1.30 [ 0.73, 1.87 ]
Subtotal (95% CI) 115 116 100.0 % 1.04 [ 0.65, 1.44 ]
Heterogeneity: Chi2 = 1.52, df = 1 (P = 0.22); I2 =34%
Test for overall effect: Z = 5.14 (P < 0.00001)
4 Question 4: ability to maintain erection
Fava 2006 71 3.7 (1.69) 71 2.8 (1.69) 52.7 % 0.90 [ 0.34, 1.46 ]
Nurnberg 2003 44 4.2 (1.2) 45 2.7 (1.6) 47.3 % 1.50 [ 0.91, 2.09 ]
Subtotal (95% CI) 115 116 100.0 % 1.18 [ 0.78, 1.59 ]
Heterogeneity: Chi2 = 2.12, df = 1 (P = 0.15); I2 =53%
-4 -2 0 2 4
Favours placebo Favours sildenafil
(Continued . . . )
73Strategies for managing sexual dysfunction induced by antidepressant medication (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Sildenafil Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Test for overall effect: Z = 5.75 (P < 0.00001)
5 Intercourse satisfaction (questions 6, 7, 8)
Nurnberg 2003 44 10.7 (2.6) 45 7.2 (2.3) 100.0 % 3.50 [ 2.48, 4.52 ]
Subtotal (95% CI) 44 45 100.0 % 3.50 [ 2.48, 4.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.72 (P < 0.00001)
6 Orgasmic function (questions 9, 10)
Nurnberg 2003 44 8.1 (2.2) 45 5.6 (3.2) 100.0 % 2.50 [ 1.36, 3.64 ]
Subtotal (95% CI) 44 45 100.0 % 2.50 [ 1.36, 3.64 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.30 (P = 0.000017)
7 Sexual desire (questions 11, 12)
Nurnberg 2003 44 6.5 (1.9) 45 6 (2.3) 100.0 % 0.50 [ -0.38, 1.38 ]
Subtotal (95% CI) 44 45 100.0 % 0.50 [ -0.38, 1.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
8 Overall satisfaction (questions 13,14)
Nurnberg 2003 44 7.1 (2.3) 45 5.3 (2.2) 100.0 % 1.80 [ 0.86, 2.74 ]
Subtotal (95% CI) 44 45 100.0 % 1.80 [ 0.86, 2.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.77 (P = 0.00016)
Test for subgroup differences: Chi2 = 135.72, df = 7 (P = 0.00), I2 =95%
-4 -2 0 2 4
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Analysis 1.2. Comparison 1 Sildenafil vs placebo, Outcome 2 Endpoint Erectile Dysfunction Inventory of
Treatment Satisfaction (EDITS) scores.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 1 Sildenafil vs placebo
Outcome: 2 Endpoint Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) scores
Study or subgroup Sildenafil Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Total score
Ginsberg 2001 12 75.8 (20.3) 11 54.2 (21.9) 21.60 [ 4.30, 38.90 ]
-100 -50 0 50 100
Favours placebo Favours sildenafil
Analysis 1.3. Comparison 1 Sildenafil vs placebo, Outcome 3 Endpoint Clinical Global Impression - Sexual
Function.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 1 Sildenafil vs placebo
Outcome: 3 Endpoint Clinical Global Impression - Sexual Function
Study or subgroup Sildenafil Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Nurnberg 2008 49 2.8 (1.1) 49 3.6 (0.9) -0.80 [ -1.20, -0.40 ]
-4 -2 0 2 4
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Analysis 1.4. Comparison 1 Sildenafil vs placebo, Outcome 4 Clinical Global Impression -Sexual Function
not “much/very much improved” by endpoint.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 1 Sildenafil vs placebo
Outcome: 4 Clinical Global Impression -Sexual Function not ”much/very much improved” by endpoint
Study or subgroup sildenafil placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Males
Nurnberg 2003 20/44 43/45 54.1 % 0.48 [ 0.34, 0.66 ]
Subtotal (95% CI) 44 45 54.1 % 0.48 [ 0.34, 0.66 ]
Total events: 20 (sildenafil), 43 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.42 (P = 0.000010)
2 Females
Nurnberg 2008 14/49 36/49 45.9 % 0.39 [ 0.24, 0.62 ]
Subtotal (95% CI) 49 49 45.9 % 0.39 [ 0.24, 0.62 ]
Total events: 14 (sildenafil), 36 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.91 (P = 0.000093)
Total (95% CI) 93 94 100.0 % 0.44 [ 0.33, 0.58 ]
Total events: 34 (sildenafil), 79 (placebo)
Heterogeneity: Chi2 = 0.49, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 5.87 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.47, df = 1 (P = 0.49), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
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Analysis 1.5. Comparison 1 Sildenafil vs placebo, Outcome 5 Endpoint Arizona Sexual Experience Scale
(ASEX) total scores.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 1 Sildenafil vs placebo
Outcome: 5 Endpoint Arizona Sexual Experience Scale (ASEX) total scores
Study or subgroup Sildenafil Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Males
Ginsberg 2001 12 13 (3) 11 17.2 (4.3) 15.6 % -4.20 [ -7.26, -1.14 ]
Nurnberg 2003 44 14.8 (4.8) 45 19.6 (4.8) 36.6 % -4.80 [ -6.79, -2.81 ]
Subtotal (95% CI) 56 56 52.2 % -4.62 [ -6.29, -2.95 ]
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 5.42 (P < 0.00001)
2 Females
Nurnberg 2008 49 19.5 (4.6) 49 20 (4.2) 47.8 % -0.50 [ -2.24, 1.24 ]
Subtotal (95% CI) 49 49 47.8 % -0.50 [ -2.24, 1.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.57)
Total (95% CI) 105 105 100.0 % -2.65 [ -3.86, -1.44 ]
Heterogeneity: Chi2 = 11.29, df = 2 (P = 0.004); I2 =82%
Test for overall effect: Z = 4.30 (P = 0.000017)
Test for subgroup differences: Chi2 = 11.19, df = 1 (P = 0.00), I2 =91%
-4 -2 0 2 4
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Analysis 1.6. Comparison 1 Sildenafil vs placebo, Outcome 6 Males: endpoint Arizona Sexual Experience
Scale scores.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 1 Sildenafil vs placebo
Outcome: 6 Males: endpoint Arizona Sexual Experience Scale scores
Study or subgroup Sildenafil Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Total score
Ginsberg 2001 12 13 (3) 11 17.2 (4.3) 29.9 % -4.20 [ -7.26, -1.14 ]
Nurnberg 2003 44 14.8 (4.8) 45 19.6 (4.8) 70.1 % -4.80 [ -6.79, -2.81 ]
Subtotal (95% CI) 56 56 100.0 % -4.62 [ -6.29, -2.95 ]
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 5.42 (P < 0.00001)
2 Sexual desire
Nurnberg 2003 44 2.9 (1) 45 3.5 (1.3) 100.0 % -0.60 [ -1.08, -0.12 ]
Subtotal (95% CI) 44 45 100.0 % -0.60 [ -1.08, -0.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.44 (P = 0.015)
3 Arousal
Nurnberg 2003 44 3 (1) 45 3.6 (1.2) 100.0 % -0.60 [ -1.06, -0.14 ]
Subtotal (95% CI) 44 45 100.0 % -0.60 [ -1.06, -0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.56 (P = 0.010)
4 Erectile function
Nurnberg 2003 44 2.9 (1.1) 45 4.1 (1.1) 100.0 % -1.20 [ -1.66, -0.74 ]
Subtotal (95% CI) 44 45 100.0 % -1.20 [ -1.66, -0.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.15 (P < 0.00001)
5 Orgasm (ability)
Nurnberg 2003 44 3.2 (1.3) 45 4.6 (1.1) 100.0 % -1.40 [ -1.90, -0.90 ]
Subtotal (95% CI) 44 45 100.0 % -1.40 [ -1.90, -0.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.48 (P < 0.00001)
6 Orgasm (satisfaction)
Nurnberg 2003 44 2.8 (1.3) 45 3.8 (1.5) 100.0 % -1.00 [ -1.58, -0.42 ]
Subtotal (95% CI) 44 45 100.0 % -1.00 [ -1.58, -0.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.36 (P = 0.00077)
Test for subgroup differences: Chi2 = 26.81, df = 5 (P = 0.00), I2 =81%
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Analysis 1.7. Comparison 1 Sildenafil vs placebo, Outcome 7 Endpoint MGH-Sexual Functioning
Questionnaire scores.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 1 Sildenafil vs placebo
Outcome: 7 Endpoint MGH-Sexual Functioning Questionnaire scores
Study or subgroup Sildenafil Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Total score
Nurnberg 2003 44 13.9 (5.7) 45 20.6 (4.3) -6.70 [ -8.80, -4.60 ]
2 Sexual desire
Nurnberg 2003 44 2.5 (1.2) 45 3.2 (1.2) -0.70 [ -1.20, -0.20 ]
3 Arousal
Nurnberg 2003 44 2.6 (1.3) 45 3.7 (1.3) -1.10 [ -1.64, -0.56 ]
4 Erectile function
Nurnberg 2003 44 3.1 (1.6) 45 4.8 (1.2) -1.70 [ -2.29, -1.11 ]
5 Orgasm (ability)
Nurnberg 2003 44 2.7 (1.3) 45 4.5 (1) -1.80 [ -2.28, -1.32 ]
6 Overall satisfaction
Nurnberg 2003 44 3 (1.4) 45 4.3 (1) -1.30 [ -1.81, -0.79 ]
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Analysis 1.8. Comparison 1 Sildenafil vs placebo, Outcome 8 Sexual dysfunction defined by Arizona Sexual
Experience Scale at trial endpoint.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 1 Sildenafil vs placebo
Outcome: 8 Sexual dysfunction defined by Arizona Sexual Experience Scale at trial endpoint
Study or subgroup Sildenafil Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ginsberg 2001 1/11 5/10 0.18 [ 0.03, 1.30 ]
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Analysis 1.9. Comparison 1 Sildenafil vs placebo, Outcome 9 Dropouts.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 1 Sildenafil vs placebo
Outcome: 9 Dropouts
Study or subgroup Sildenafil Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fava 2006 4/71 9/71 30.8 % 0.44 [ 0.14, 1.38 ]
Ginsberg 2001 3/12 4/11 14.3 % 0.69 [ 0.20, 2.41 ]
Nurnberg 2008 10/49 12/49 41.1 % 0.83 [ 0.40, 1.75 ]
Nurnberg 2003 3/45 4/45 13.7 % 0.75 [ 0.18, 3.16 ]
Total (95% CI) 177 176 100.0 % 0.68 [ 0.41, 1.14 ]
Total events: 20 (Sildenafil), 29 (Placebo)
Heterogeneity: Chi2 = 0.85, df = 3 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Sildenafil vs placebo, Outcome 10 Endpoint Hamilton Rating Scale for
Depression score.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 1 Sildenafil vs placebo
Outcome: 10 Endpoint Hamilton Rating Scale for Depression score
Study or subgroup Sildenafil Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Nurnberg 2008 49 4 (3.5) 49 3.9 (3.6) 50.7 % 0.10 [ -1.31, 1.51 ]
Nurnberg 2003 44 3.5 (2.9) 45 5.5 (3.9) 49.3 % -2.00 [ -3.43, -0.57 ]
Total (95% CI) 93 94 100.0 % -0.94 [ -1.94, 0.07 ]
Heterogeneity: Chi2 = 4.23, df = 1 (P = 0.04); I2 =76%
Test for overall effect: Z = 1.83 (P = 0.067)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Sildenafil vs placebo, Outcome 11 Loss of remission: Hamilton Rating Scale for
Depression score > 9.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 1 Sildenafil vs placebo
Outcome: 11 Loss of remission: Hamilton Rating Scale for Depression score > 9
Study or subgroup Sildenafil Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fava 2006 0/71 0/71 0.0 [ 0.0, 0.0 ]
Nurnberg 2008 1/49 3/49 0.33 [ 0.04, 3.09 ]
Nurnberg 2003 0/45 0/45 0.0 [ 0.0, 0.0 ]
Total (95% CI) 165 165 0.33 [ 0.04, 3.09 ]
Total events: 1 (Sildenafil), 3 (Placebo)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Sildenafil vs placebo, Outcome 12 Global Efficacy Questionnaire (questions 1
& 2).
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 1 Sildenafil vs placebo
Outcome: 12 Global Efficacy Questionnaire (questions 1 % 2)
Study or subgroup Sildenafil Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Improvement in erections
Fava 2006 50/71 20/71 50.0 % 2.50 [ 1.67, 3.73 ]
Subtotal (95% CI) 71 71 50.0 % 2.50 [ 1.67, 3.73 ]
Total events: 50 (Sildenafil), 20 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.48 (P < 0.00001)
2 Improvement in ability to have sexual intercourse
Fava 2006 51/71 20/71 50.0 % 2.55 [ 1.71, 3.80 ]
Subtotal (95% CI) 71 71 50.0 % 2.55 [ 1.71, 3.80 ]
Total events: 51 (Sildenafil), 20 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.60 (P < 0.00001)
Total (95% CI) 142 142 100.0 % 2.53 [ 1.90, 3.35 ]
Total events: 101 (Sildenafil), 40 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 6.42 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.95), I2 =0.0%
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Analysis 1.13. Comparison 1 Sildenafil vs placebo, Outcome 13 Global efficacy questionnaire (question 3).
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 1 Sildenafil vs placebo
Outcome: 13 Global efficacy questionnaire (question 3)
Study or subgroup Sildenafil Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Question 3: Frequency of erection that allowed satisfactory sexual intercourse
Fava 2006 67 2.5 (1.64) 62 1.3 (1.57) 100.0 % 1.20 [ 0.65, 1.75 ]
Total (95% CI) 67 62 100.0 % 1.20 [ 0.65, 1.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.25 (P = 0.000022)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Sildenafil vs placebo, Outcome 14 Endpoint Sexual Function Questionnaire
(SFQ).
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 1 Sildenafil vs placebo
Outcome: 14 Endpoint Sexual Function Questionnaire (SFQ)
Study or subgroup Sildenafil Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Desire
Nurnberg 2008 49 17.3 (5.1) 49 16.4 (5.2) 0.90 [ -1.14, 2.94 ]
2 Arousal-sensation
Nurnberg 2008 49 10.3 (4.2) 49 10.4 (4.2) -0.10 [ -1.76, 1.56 ]
3 Arousal-lubrication
Nurnberg 2008 49 6.2 (2.2) 49 5.6 (2.3) 0.60 [ -0.29, 1.49 ]
4 Orgasm
Nurnberg 2008 49 8.6 (3.9) 49 8.6 (3) 0.0 [ -1.38, 1.38 ]
5 Enjoyment
Nurnberg 2008 49 18 (5.7) 49 16.9 (5.4) 1.10 [ -1.10, 3.30 ]
6 Pain
Nurnberg 2008 49 14.1 (1.9) 49 13.9 (1.8) 0.20 [ -0.53, 0.93 ]
7 Partner
Nurnberg 2008 49 8.2 (1.6) 49 7.9 (2) 0.30 [ -0.42, 1.02 ]
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Analysis 1.15. Comparison 1 Sildenafil vs placebo, Outcome 15 UNM Sexual Function Inventory.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 1 Sildenafil vs placebo
Outcome: 15 UNM Sexual Function Inventory
Study or subgroup Sildenafil Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Total score
Nurnberg 2008 49 20.2 (6.4) 49 22 (6.1) -1.80 [ -4.28, 0.68 ]
2 Desire
Nurnberg 2008 49 4.1 (1.5) 49 4.3 (1.6) -0.20 [ -0.81, 0.41 ]
3 Sexual arousal
Nurnberg 2008 49 4.3 (1.5) 49 4.4 (1.5) -0.10 [ -0.69, 0.49 ]
4 Lubrication
Nurnberg 2008 49 3.4 (1.4) 49 3.9 (1.6) -0.50 [ -1.10, 0.10 ]
5 Ability to reach orgasm
Nurnberg 2008 49 4.6 (1.6) 49 5 (1.4) -0.40 [ -1.00, 0.20 ]
6 Overall satisfaction
Nurnberg 2008 49 4 (1.5) 49 4.4 (1.5) -0.40 [ -0.99, 0.19 ]
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Analysis 1.16. Comparison 1 Sildenafil vs placebo, Outcome 16 Females: endpoint Arizona Sexual
Experience Scale scores.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 1 Sildenafil vs placebo
Outcome: 16 Females: endpoint Arizona Sexual Experience Scale scores
Study or subgroup Sildenafil Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Total score
Nurnberg 2008 49 19.5 (4.6) 49 20 (4.2) -0.50 [ -2.24, 1.24 ]
2 Sexual desire
Nurnberg 2008 49 4.2 (1.2) 49 4.2 (1.2) 0.0 [ -0.48, 0.48 ]
3 Arousal
Nurnberg 2008 49 4.1 (1.1) 49 4.1 (1.1) 0.0 [ -0.44, 0.44 ]
4 Orgasm (ability)
Nurnberg 2008 49 4.3 (1.2) 49 4.5 (1) -0.20 [ -0.64, 0.24 ]
5 Orgasm (satisfaction)
Nurnberg 2008 49 3.6 (1.4) 49 3.8 (1.3) -0.20 [ -0.73, 0.33 ]
6 Lubrication
Nurnberg 2008 49 3.3 (1.1) 49 3.5 (1.3) -0.20 [ -0.68, 0.28 ]
-1 -0.5 0 0.5 1
Favours sildenafil Favours placebo
87Strategies for managing sexual dysfunction induced by antidepressant medication (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.1. Comparison 2 Tadalafil vs placebo, Outcome 1 Global Assessment Questions.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 2 Tadalafil vs placebo
Outcome: 1 Global Assessment Questions
Study or subgroup Tadalafil Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Has the treatment you have been taking improved your erectile function?
Evliyao lu 2011 23/25 2/25 100.0 % 11.50 [ 3.03, 43.67 ]
Subtotal (95% CI) 25 25 100.0 % 11.50 [ 3.03, 43.67 ]
Total events: 23 (Tadalafil), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.59 (P = 0.00033)
2 Has the treatment improved your ability to engage in sexual activity?
Evliyao lu 2011 23/25 2/25 100.0 % 11.50 [ 3.03, 43.67 ]
Subtotal (95% CI) 25 25 100.0 % 11.50 [ 3.03, 43.67 ]
Total events: 23 (Tadalafil), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.59 (P = 0.00033)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 1.00), I2 =0.0%
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Analysis 2.2. Comparison 2 Tadalafil vs placebo, Outcome 2 Endpoint Sexual Encounter Profile (SEP).
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 2 Tadalafil vs placebo
Outcome: 2 Endpoint Sexual Encounter Profile (SEP)
Study or subgroup Tadalafil Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Question 2: Were you able to insert your penis into your partner’s vagina?
Evliyao lu 2011 7/25 3/25 100.0 % 2.33 [ 0.68, 8.01 ]
Subtotal (95% CI) 25 25 100.0 % 2.33 [ 0.68, 8.01 ]
Total events: 7 (Tadalafil), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
2 Question 3: Did your erection last long enough for you to have successful intercourse?
Evliyao lu 2011 6/25 1/25 100.0 % 6.00 [ 0.78, 46.29 ]
Subtotal (95% CI) 25 25 100.0 % 6.00 [ 0.78, 46.29 ]
Total events: 6 (Tadalafil), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.72 (P = 0.086)
3 Question 4: Were you satisfied with the hardness of your erection?
Evliyao lu 2011 6/25 1/25 100.0 % 6.00 [ 0.78, 46.29 ]
Subtotal (95% CI) 25 25 100.0 % 6.00 [ 0.78, 46.29 ]
Total events: 6 (Tadalafil), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.72 (P = 0.086)
4 Question 5: Were you satisfied overall with this sexual experience?
Evliyao lu 2011 6/25 1/25 100.0 % 6.00 [ 0.78, 46.29 ]
Subtotal (95% CI) 25 25 100.0 % 6.00 [ 0.78, 46.29 ]
Total events: 6 (Tadalafil), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.72 (P = 0.086)
Test for subgroup differences: Chi2 = 1.18, df = 3 (P = 0.76), I2 =0.0%
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Analysis 2.3. Comparison 2 Tadalafil vs placebo, Outcome 3 Dropouts.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 2 Tadalafil vs placebo
Outcome: 3 Dropouts
Study or subgroup Tadalafil Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Overall
Evliyao lu 2011 1/26 3/28 0.36 [ 0.04, 3.24 ]
Subtotal (95% CI) 26 28 0.36 [ 0.04, 3.24 ]
Total events: 1 (Tadalafil), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
2 Lack of efficacy
Evliyao lu 2011 1/26 3/28 0.36 [ 0.04, 3.24 ]
Subtotal (95% CI) 26 28 0.36 [ 0.04, 3.24 ]
Total events: 1 (Tadalafil), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
3 Adverse effects
Evliyao lu 2011 0/26 0/28 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 26 28 0.0 [ 0.0, 0.0 ]
Total events: 0 (Tadalafil), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 1.00), I2 =0.0%
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Analysis 3.1. Comparison 3 Bupropion vs placebo, Outcome 1 Endpoint scale total scores.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 3 Bupropion vs placebo
Outcome: 1 Endpoint scale total scores
Study or subgroup Bupropion Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 International Index of Erectile Function (IIEF)
Safarinejad 2010 114 61.3 (10.4) 113 41.2 (12.3) 45.5 % 1.76 [ 1.45, 2.07 ]
Subtotal (95% CI) 114 113 45.5 % 1.76 [ 1.45, 2.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 11.23 (P < 0.00001)
2 Female Sexual Function Index (FSFI)
Safarinejad 2011 106 25.9 (5.12) 107 17.2 (4.9) 43.1 % 1.73 [ 1.41, 2.05 ]
Subtotal (95% CI) 106 107 43.1 % 1.73 [ 1.41, 2.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 10.74 (P < 0.00001)
3 Changes in Sexual Functioning Questionnaire (CSFQ)
Clayton 2004 20 48 (9.83) 22 43.5 (7.74) 11.3 % 0.50 [ -0.11, 1.12 ]
Subtotal (95% CI) 20 22 11.3 % 0.50 [ -0.11, 1.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
Total (95% CI) 240 242 100.0 % 1.60 [ 1.40, 1.81 ]
Heterogeneity: Chi2 = 13.89, df = 2 (P = 0.00096); I2 =86%
Test for overall effect: Z = 15.17 (P < 0.00001)
Test for subgroup differences: Chi2 = 13.89, df = 2 (P = 0.00), I2 =86%
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Analysis 3.2. Comparison 3 Bupropion vs placebo, Outcome 2 Response (as defined by study).
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 3 Bupropion vs placebo
Outcome: 2 Response (as defined by study)
Study or subgroup Bupropion Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 50% reduction Arizona Sexual Experiences Scale (ASEX)
DeBattista 2005 1/20 1/21 32.8 % 1.05 [ 0.07, 15.68 ]
Masand 2001 0/15 1/15 50.4 % 0.33 [ 0.01, 7.58 ]
Subtotal (95% CI) 35 36 83.3 % 0.62 [ 0.09, 4.41 ]
Total events: 1 (Bupropion), 2 (Placebo)
Heterogeneity: Chi2 = 0.30, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
2 Clinical Global Impression (CGI-SF) 2-point improvement
Safarinejad 2011 92/106 0/107 16.7 % 186.73 [ 11.74, 2969.23 ]
Subtotal (95% CI) 106 107 16.7 % 186.73 [ 11.74, 2969.23 ]
Total events: 92 (Bupropion), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.71 (P = 0.00021)
Total (95% CI) 141 143 100.0 % 31.77 [ 10.10, 99.89 ]
Total events: 93 (Bupropion), 2 (Placebo)
Heterogeneity: Chi2 = 15.86, df = 2 (P = 0.00036); I2 =87%
Test for overall effect: Z = 5.92 (P < 0.00001)
Test for subgroup differences: Chi2 = 10.88, df = 1 (P = 0.00), I2 =91%
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Analysis 3.3. Comparison 3 Bupropion vs placebo, Outcome 3 Endpoint International Index of Erectile
Function (IIEF).
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 3 Bupropion vs placebo
Outcome: 3 Endpoint International Index of Erectile Function (IIEF)
Study or subgroup Bupropion Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Total score
Safarinejad 2010 114 61.3 (10.4) 113 41.2 (12.3) 100.0 % 20.10 [ 17.14, 23.06 ]
Subtotal (95% CI) 114 113 100.0 % 20.10 [ 17.14, 23.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 13.29 (P < 0.00001)
2 Erectile function
Safarinejad 2010 114 27.4 (2.8) 113 18.1 (5.4) 100.0 % 9.30 [ 8.18, 10.42 ]
Subtotal (95% CI) 114 113 100.0 % 9.30 [ 8.18, 10.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 16.27 (P < 0.00001)
3 Orgasmic function
Safarinejad 2010 114 8.3 (2.1) 113 5.6 (2.1) 100.0 % 2.70 [ 2.15, 3.25 ]
Subtotal (95% CI) 114 113 100.0 % 2.70 [ 2.15, 3.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.69 (P < 0.00001)
4 Sexual desire
Safarinejad 2010 114 7.7 (1.4) 113 5.6 (1.2) 100.0 % 2.10 [ 1.76, 2.44 ]
Subtotal (95% CI) 114 113 100.0 % 2.10 [ 1.76, 2.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 12.14 (P < 0.00001)
5 Intercourse satisfaction
Safarinejad 2010 114 10.3 (2.4) 113 6.7 (2.2) 100.0 % 3.60 [ 3.00, 4.20 ]
Subtotal (95% CI) 114 113 100.0 % 3.60 [ 3.00, 4.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 11.78 (P < 0.00001)
6 Overall satisfaction
Safarinejad 2010 114 7.6 (2.4) 113 5 (2.3) 100.0 % 2.60 [ 1.99, 3.21 ]
Subtotal (95% CI) 114 113 100.0 % 2.60 [ 1.99, 3.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.33 (P < 0.00001)
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Analysis 3.4. Comparison 3 Bupropion vs placebo, Outcome 4 Endpoint Female Sexual Function Index
score.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 3 Bupropion vs placebo
Outcome: 4 Endpoint Female Sexual Function Index score
Study or subgroup Bupropion Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Total score
Safarinejad 2011 106 25.9 (5.12) 107 17.2 (4.9) 8.70 [ 7.35, 10.05 ]
2 Desire
Safarinejad 2011 106 4.1 (0.7) 107 2.2 (0.4) 1.90 [ 1.75, 2.05 ]
3 Arousal
Safarinejad 2011 106 4.4 (0.6) 107 3.1 (0.4) 1.30 [ 1.16, 1.44 ]
4 Lubrication
Safarinejad 2011 106 4.4 (0.4) 107 2.5 (0.3) 1.90 [ 1.80, 2.00 ]
5 Orgasm
Safarinejad 2011 106 4.4 (0.5) 107 2.5 (0.4) 1.90 [ 1.78, 2.02 ]
6 Satisfaction
Safarinejad 2011 106 4.2 (0.7) 107 2.6 (0.3) 1.60 [ 1.46, 1.74 ]
7 Pain
Safarinejad 2011 106 4.4 (0.4) 107 4.3 (0.4) 0.10 [ -0.01, 0.21 ]
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Analysis 3.5. Comparison 3 Bupropion vs placebo, Outcome 5 Endpoint Changes in Sexual Functioning
Questionnaire score.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 3 Bupropion vs placebo
Outcome: 5 Endpoint Changes in Sexual Functioning Questionnaire score
Study or subgroup Bupropion Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Total score
Clayton 2004 20 48 (9.83) 22 43.5 (7.74) 4.50 [ -0.89, 9.89 ]
2 Desire/interest
Clayton 2004 20 8.85 (2.7) 22 7.91 (2.33) 0.94 [ -0.59, 2.47 ]
3 Desire/frequency
Clayton 2004 20 6.65 (1.05) 22 5.77 (1.15) 0.88 [ 0.21, 1.55 ]
4 Arousal/excitement
Clayton 2004 20 10.5 (2.8) 22 9.27 (2.55) 1.23 [ -0.40, 2.86 ]
5 Completion/orgasm
Clayton 2004 20 10.05 (2.8) 22 8.91 (3.16) 1.14 [ -0.66, 2.94 ]
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Analysis 3.6. Comparison 3 Bupropion vs placebo, Outcome 6 Dropouts.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 3 Bupropion vs placebo
Outcome: 6 Dropouts
Study or subgroup Bupropion Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Clayton 2004 9/29 4/26 2.02 [ 0.70, 5.78 ]
DeBattista 2005 0/20 0/21 0.0 [ 0.0, 0.0 ]
Masand 2001 1/16 0/15 2.82 [ 0.12, 64.39 ]
Safarinejad 2010 13/117 15/117 0.87 [ 0.43, 1.74 ]
Safarinejad 2011 9/109 10/109 0.90 [ 0.38, 2.13 ]
Total (95% CI) 291 288 1.08 [ 0.67, 1.72 ]
Total events: 32 (Bupropion), 29 (Placebo)
Heterogeneity: Chi2 = 2.27, df = 3 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Not applicable
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Analysis 3.7. Comparison 3 Bupropion vs placebo, Outcome 7 Endpoint Hamilton Rating Scale for
Depression score.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 3 Bupropion vs placebo
Outcome: 7 Endpoint Hamilton Rating Scale for Depression score
Study or subgroup Bupropion Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Clayton 2004 20 4.05 (3.49) 22 4.65 (3.16) -0.60 [ -2.62, 1.42 ]
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Analysis 3.8. Comparison 3 Bupropion vs placebo, Outcome 8 Endpoint Clinical Global Impression (CGI -
SF).
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 3 Bupropion vs placebo
Outcome: 8 Endpoint Clinical Global Impression (CGI - SF)
Study or subgroup Bupropion Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Male
Safarinejad 2010 114 2.4 (1.2) 113 3.9 (1.1) 19.7 % -1.50 [ -1.80, -1.20 ]
Subtotal (95% CI) 114 113 19.7 % -1.50 [ -1.80, -1.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.82 (P < 0.00001)
2 Female
Safarinejad 2011 106 2.4 (0.6) 107 4.2 (0.5) 80.3 % -1.80 [ -1.95, -1.65 ]
Subtotal (95% CI) 106 107 80.3 % -1.80 [ -1.95, -1.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 23.77 (P < 0.00001)
Total (95% CI) 220 220 100.0 % -1.74 [ -1.87, -1.61 ]
Heterogeneity: Chi2 = 3.10, df = 1 (P = 0.08); I2 =68%
Test for overall effect: Z = 25.66 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.10, df = 1 (P = 0.08), I2 =68%
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Analysis 3.9. Comparison 3 Bupropion vs placebo, Outcome 9 Endpoint ASEX.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 3 Bupropion vs placebo
Outcome: 9 Endpoint ASEX
Study or subgroup Bupropion Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Total score
Safarinejad 2010 114 15.5 (4.3) 113 21.5 (4.7) -6.00 [ -7.17, -4.83 ]
2 Erectile function
Safarinejad 2010 114 3.2 (1) 113 4.2 (1.2) -1.00 [ -1.29, -0.71 ]
3 Sexual desire
Safarinejad 2010 114 3.1 (1.1) 113 4.3 (1.1) -1.20 [ -1.49, -0.91 ]
4 Arousal
Safarinejad 2010 114 3.2 (1) 113 4 (1) -0.80 [ -1.06, -0.54 ]
5 Ability to reach orgasm
Safarinejad 2010 114 3 (0.9) 113 4.6 (1) -1.60 [ -1.85, -1.35 ]
6 Satisfaction with orgasm
Safarinejad 2010 114 3.1 (1.1) 113 4.3 (1.2) -1.20 [ -1.50, -0.90 ]
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Analysis 3.10. Comparison 3 Bupropion vs placebo, Outcome 10 Endpoint EDITS (participant).
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 3 Bupropion vs placebo
Outcome: 10 Endpoint EDITS (participant)
Study or subgroup Bupropion Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Total score
Safarinejad 2010 114 67.4 (10.2) 113 36.3 (11.7) 31.10 [ 28.24, 33.96 ]
2 Overall satisfaction
Safarinejad 2010 114 2.6 (0.14) 113 0.9 (0.22) 1.70 [ 1.65, 1.75 ]
3 Expectations
Safarinejad 2010 114 2.2 (0.12) 113 1.1 (0.16) 1.10 [ 1.06, 1.14 ]
4 Likelihood of continuing
Safarinejad 2010 114 2.6 (0.15) 113 0.9 (0.26) 1.70 [ 1.64, 1.76 ]
5 Confidence
Safarinejad 2010 114 2.7 (0.12) 113 1.3 (0.19) 1.40 [ 1.36, 1.44 ]
6 Partner satisfaction
Safarinejad 2010 114 2.5 (0.16) 113 1 (0.18) 1.50 [ 1.46, 1.54 ]
7 Partner desire to continue treatment
Safarinejad 2010 114 2.7 (0.14) 113 1.2 (0.18) 1.50 [ 1.46, 1.54 ]
8 Naturalness of achieving erection
Safarinejad 2010 114 3.2 (0.11) 113 2.2 (0.2) 1.00 [ 0.96, 1.04 ]
9 Naturalness of erection hardness
Safarinejad 2010 114 2.6 (0.14) 113 1.8 (0.19) 0.80 [ 0.76, 0.84 ]
10 Quickness of achieving erection
Safarinejad 2010 114 2.8 (0.12) 113 1.4 (0.12) 1.40 [ 1.37, 1.43 ]
11 Duration that erection lasts
Safarinejad 2010 114 2.7 (0.14) 113 1.2 (0.22) 1.50 [ 1.45, 1.55 ]
12 Ease of use
Safarinejad 2010 114 3.8 (0.06) 113 3.8 (0.07) 0.0 [ -0.02, 0.02 ]
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Analysis 3.11. Comparison 3 Bupropion vs placebo, Outcome 11 Endpoint EDITS (partner).
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 3 Bupropion vs placebo
Outcome: 11 Endpoint EDITS (partner)
Study or subgroup Bupropion Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Total score
Safarinejad 2010 114 64.1 (3.2) 113 36.1 (3.42) 28.00 [ 27.14, 28.86 ]
2 Overall satisfaction
Safarinejad 2010 114 2.4 (0.12) 113 1 (0.18) 1.40 [ 1.36, 1.44 ]
3 Expectations
Safarinejad 2010 114 2.2 (0.15) 113 0.8 (0.24) 1.40 [ 1.35, 1.45 ]
4 Sexual desirability
Safarinejad 2010 114 2.4 (0.1) 113 2.1 (0.13) 0.30 [ 0.27, 0.33 ]
5 Participant’s feelings about continuing treatment
Safarinejad 2010 114 2.7 (0.16) 113 1.2 (0.23) 1.50 [ 1.45, 1.55 ]
6 Duration that erection lasts
Safarinejad 2010 114 2.5 (0.15) 113 1.2 (0.22) 1.30 [ 1.25, 1.35 ]
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Analysis 4.1. Comparison 4 Nefazodone vs sertraline, Outcome 1 Re-emergence of antidepressant-induced
sexual dysfunction (physician rated).
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 4 Nefazodone vs sertraline
Outcome: 1 Re-emergence of antidepressant-induced sexual dysfunction (physician rated)
Study or subgroup Nefazodone Sertraline Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Week 1
Ferguson 2001 7/39 18/33 0.33 [ 0.16, 0.69 ]
2 Endpoint
Ferguson 2001 10/39 25/33 0.34 [ 0.19, 0.60 ]
0.1 0.2 0.5 1 2 5 10
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Analysis 4.2. Comparison 4 Nefazodone vs sertraline, Outcome 2 Overall degree of sexual satisfaction
(participant rated).
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 4 Nefazodone vs sertraline
Outcome: 2 Overall degree of sexual satisfaction (participant rated)
Study or subgroup Nefazodone Sertraline
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Baseline
Ferguson 2001 39 71.2 (26.97) 27 65.95 (24.4) 5.25 [ -7.25, 17.75 ]
2 Week 8
Ferguson 2001 28 62.39 (37.85) 16 45.17 (34.05) 17.22 [ -4.57, 39.01 ]
3 Last rating recorded
Ferguson 2001 38 62.41 (37.89) 26 41.52 (33.84) 20.89 [ 3.16, 38.62 ]
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Analysis 4.3. Comparison 4 Nefazodone vs sertraline, Outcome 3 Dropouts.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 4 Nefazodone vs sertraline
Outcome: 3 Dropouts
Study or subgroup Nefazodone Sertraline Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Overall
Ferguson 2001 12/41 12/34 0.83 [ 0.43, 1.60 ]
2 Attributed to adverse effects
Ferguson 2001 5/41 9/34 0.46 [ 0.17, 1.25 ]
0.1 0.2 0.5 1 2 5 10
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Analysis 4.4. Comparison 4 Nefazodone vs sertraline, Outcome 4 Hamilton Rating Scale for Depression
score.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 4 Nefazodone vs sertraline
Outcome: 4 Hamilton Rating Scale for Depression score
Study or subgroup Nefazodone Sertraline
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Baseline
Ferguson 2001 42 11.54 (6.85) 30 10.62 (5.9) 0.92 [ -2.04, 3.88 ]
2 Week 8
Ferguson 2001 42 6.88 (6.81) 30 8.45 (5.86) -1.57 [ -4.51, 1.37 ]
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Analysis 5.1. Comparison 5 Ginkgo biloba vs placebo, Outcome 1 Endpoint sexual function ratings
(investigator questionnaire).
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 5 Ginkgo biloba vs placebo
Outcome: 1 Endpoint sexual function ratings (investigator questionnaire)
Study or subgroup Ginkgo biloba Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Sexual desire
Kang 2002 12 2.91 (1.31) 13 2.76 (1.58) 0.15 [ -0.98, 1.28 ]
2 Overall sexual function
Kang 2002 12 2.75 (1.28) 13 3.23 (1.23) -0.48 [ -1.47, 0.51 ]
3 Erection maintenance time
Kang 2002 12 3.6 (1.17) 13 3.5 (0.97) 0.10 [ -0.75, 0.95 ]
4 Orgasm frequency
Kang 2002 12 2.54 (1.5) 13 2 (1.35) 0.54 [ -0.58, 1.66 ]
5 Satisfaction to orgasm
Kang 2002 12 2.72 (1.1) 13 3.84 (1.14) -1.12 [ -2.00, -0.24 ]
-10 -5 0 5 10
Favours placebo Favours Ginkgo
104Strategies for managing sexual dysfunction induced by antidepressant medication (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.2. Comparison 5 Ginkgo biloba vs placebo, Outcome 2 Sexual Dysfunction Scale (investigator
developed).
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 5 Ginkgo biloba vs placebo
Outcome: 2 Sexual Dysfunction Scale (investigator developed)
Study or subgroup Ginkgo biloba Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Baseline
Wheatley 2004 11 14.4 (3.08) 13 12.6 (4.11) 1.80 [ -1.08, 4.68 ]
2 Week 12
Wheatley 2004 11 10.9 (7.69) 13 7.1 (6.45) 3.80 [ -1.94, 9.54 ]
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Analysis 5.3. Comparison 5 Ginkgo biloba vs placebo, Outcome 3 Dropouts.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 5 Ginkgo biloba vs placebo
Outcome: 3 Dropouts
Study or subgroup Ginkgo biloba placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kang 2002 7/19 5/18 1.33 [ 0.51, 3.43 ]
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Analysis 6.1. Comparison 6 Granisetron vs placebo, Outcome 1 Change from baseline on Sexual Side
Effects Scale (SSES) total score.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 6 Granisetron vs placebo
Outcome: 1 Change from baseline on Sexual Side Effects Scale (SSES) total score
Study or subgroup Granisetron Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Nelson 2001 20 2.8 (3.1) 20 2.7 (4.3) 0.10 [ -2.22, 2.42 ]
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Analysis 6.2. Comparison 6 Granisetron vs placebo, Outcome 2 Endpoint Feiger Sexual Function and
Satisfaction Questionnaire score.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 6 Granisetron vs placebo
Outcome: 2 Endpoint Feiger Sexual Function and Satisfaction Questionnaire score
Study or subgroup Granisetron Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Total score
Jespersen 2004 5 18 (6.8) 7 16.4 (5.1) 1.60 [ -5.46, 8.66 ]
2 Item 1
Jespersen 2004 5 3.3 (1) 7 1.9 (0.7) 1.40 [ 0.38, 2.42 ]
3 Item 2
Jespersen 2004 5 4.3 (1) 7 3.1 (1.1) 1.20 [ 0.00, 2.40 ]
4 Item 3
Jespersen 2004 5 2.3 (1.9) 7 3.4 (1.7) -1.10 [ -3.19, 0.99 ]
5 Item 4
Jespersen 2004 5 2.3 (1.9) 7 2.6 (1.7) -0.30 [ -2.39, 1.79 ]
-10 -5 0 5 10
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(. . . Continued)
Study or subgroup Granisetron Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
6 Item 5
Jespersen 2004 5 3 (1.2) 7 2.7 (1.3) 0.30 [ -1.13, 1.73 ]
7 Item 6
Jespersen 2004 5 3 (1.2) 7 2.7 (1.3) 0.30 [ -1.13, 1.73 ]
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Analysis 6.3. Comparison 6 Granisetron vs placebo, Outcome 3 Endpoint Arizona Sexual Experience Scale
(ASEX) score.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 6 Granisetron vs placebo
Outcome: 3 Endpoint Arizona Sexual Experience Scale (ASEX) score
Study or subgroup Granisetron Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Total score
Jespersen 2004 5 20.3 (9.7) 7 12.4 (6.5) 7.90 [ -1.87, 17.67 ]
2 Sexual desire
Jespersen 2004 5 4.3 (2.4) 7 2.9 (1.7) 1.40 [ -1.05, 3.85 ]
3 Arousal
Jespersen 2004 5 4.3 (2.4) 7 2.9 (1.7) 1.40 [ -1.05, 3.85 ]
4 Lubrication
Jespersen 2004 5 3.8 (2.6) 7 3.4 (1.9) 0.40 [ -2.28, 3.08 ]
5 Orgasm (ability)
Jespersen 2004 5 4.3 (2.1) 7 3.6 (1.3) 0.70 [ -1.38, 2.78 ]
6 Orgasm (satisfaction)
Jespersen 2004 5 3.8 (0.5) 7 2.8 (0.8) 1.00 [ 0.26, 1.74 ]
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Analysis 6.4. Comparison 6 Granisetron vs placebo, Outcome 4 Dropouts.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 6 Granisetron vs placebo
Outcome: 4 Dropouts
Study or subgroup Granisetron Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Jespersen 2004 2/5 0/7 6.67 [ 0.39, 114.78 ]
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Analysis 6.5. Comparison 6 Granisetron vs placebo, Outcome 5 Recurrence of mood symptoms.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 6 Granisetron vs placebo
Outcome: 5 Recurrence of mood symptoms
Study or subgroup granisetron placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nelson 2001 1/22 0/21 100.0 % 2.87 [ 0.12, 66.75 ]
Total (95% CI) 22 21 100.0 % 2.87 [ 0.12, 66.75 ]
Total events: 1 (granisetron), 0 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 7.1. Comparison 7 VML-670 vs placebo, Outcome 1 Absence of sexual dysfunction at end point.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 7 VML-670 vs placebo
Outcome: 1 Absence of sexual dysfunction at end point
Study or subgroup VML-670 placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Baldwin 2008 48/138 36/128 100.0 % 1.24 [ 0.86, 1.77 ]
Total (95% CI) 138 128 100.0 % 1.24 [ 0.86, 1.77 ]
Total events: 48 (VML-670), 36 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 7.2. Comparison 7 VML-670 vs placebo, Outcome 2 ’Improved’ or ’much improved’ on Clinical
Global Impression.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 7 VML-670 vs placebo
Outcome: 2 ’Improved’ or ’much improved’ on Clinical Global Impression
Study or subgroup VML-670 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Baldwin 2008 24/138 18/128 100.0 % 1.24 [ 0.71, 2.17 ]
Total (95% CI) 138 128 100.0 % 1.24 [ 0.71, 2.17 ]
Total events: 24 (VML-670), 18 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 7.3. Comparison 7 VML-670 vs placebo, Outcome 3 Change in Arizona Sexual Experiences Scale
(ASEX) item scores.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 7 VML-670 vs placebo
Outcome: 3 Change in Arizona Sexual Experiences Scale (ASEX) item scores
Study or subgroup VML-670 Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 How strong is your sexual drive?
Baldwin 2008 133 -0.7 (1.14) 122 -0.6 (0.98) 22.0 % -0.10 [ -0.36, 0.16 ]
Subtotal (95% CI) 133 122 22.0 % -0.10 [ -0.36, 0.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
2 How easily are you sexually aroused?
Baldwin 2008 131 -0.7 (1.14) 122 -0.5 (1.05) 20.5 % -0.20 [ -0.47, 0.07 ]
Subtotal (95% CI) 131 122 20.5 % -0.20 [ -0.47, 0.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
3 Females: how easily does your vagina become moist or wet?
Baldwin 2008 93 -0.3 (1.08) 87 -0.4 (1.09) 14.8 % 0.10 [ -0.22, 0.42 ]
Subtotal (95% CI) 93 87 14.8 % 0.10 [ -0.22, 0.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
4 Males: can you easily get and keep an erection?
Baldwin 2008 37 -0.5 (0.87) 35 -0.1 (0.87) 9.2 % -0.40 [ -0.80, 0.00 ]
Subtotal (95% CI) 37 35 9.2 % -0.40 [ -0.80, 0.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.95 (P = 0.051)
5 How easily can you reach orgasm?
Baldwin 2008 130 -0.5 (1.12) 122 -0.5 (1.12) 19.5 % 0.0 [ -0.28, 0.28 ]
Subtotal (95% CI) 130 122 19.5 % 0.0 [ -0.28, 0.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
6 Are your orgasms satisfying?
Baldwin 2008 130 -0.4 (1.39) 122 -0.5 (1.24) 14.1 % 0.10 [ -0.22, 0.42 ]
Subtotal (95% CI) 130 122 14.1 % 0.10 [ -0.22, 0.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Total (95% CI) 654 610 100.0 % -0.07 [ -0.19, 0.05 ]
Heterogeneity: Chi2 = 5.93, df = 5 (P = 0.31); I2 =16%
Test for overall effect: Z = 1.14 (P = 0.26)
Test for subgroup differences: Chi2 = 5.93, df = 5 (P = 0.31), I2 =16%
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Analysis 7.4. Comparison 7 VML-670 vs placebo, Outcome 4 Dropouts.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 7 VML-670 vs placebo
Outcome: 4 Dropouts
Study or subgroup VML-670 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Total
Baldwin 2008 22/138 21/128 84.0 % 0.97 [ 0.56, 1.68 ]
Subtotal (95% CI) 138 128 84.0 % 0.97 [ 0.56, 1.68 ]
Total events: 22 (VML-670), 21 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
2 Attributed to adverse effects
Baldwin 2008 10/138 4/128 16.0 % 2.32 [ 0.75, 7.21 ]
Subtotal (95% CI) 138 128 16.0 % 2.32 [ 0.75, 7.21 ]
Total events: 10 (VML-670), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
Total (95% CI) 276 256 100.0 % 1.19 [ 0.73, 1.93 ]
Total events: 32 (VML-670), 25 (Placebo)
Heterogeneity: Chi2 = 1.85, df = 1 (P = 0.17); I2 =46%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Chi2 = 1.83, df = 1 (P = 0.18), I2 =45%
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Analysis 8.1. Comparison 8 Buspirone vs placebo, Outcome 1 Change in patient-rated visual analogue
scales.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 8 Buspirone vs placebo
Outcome: 1 Change in patient-rated visual analogue scales
Study or subgroup Buspirone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Overall function (total of interest, lubrication, orgasm, pleasure)
Michelson 2000 19 40.8 (64.2) 20 37.7 (67.8) 100.0 % 3.10 [ -38.33, 44.53 ]
Subtotal (95% CI) 19 20 100.0 % 3.10 [ -38.33, 44.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
2 Mood
Michelson 2000 19 1.4 (15.2) 20 0.6 (11.2) 100.0 % 0.80 [ -7.61, 9.21 ]
Subtotal (95% CI) 19 20 100.0 % 0.80 [ -7.61, 9.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
3 Energy
Michelson 2000 19 2.1 (15.1) 20 -3.2 (14.1) 100.0 % 5.30 [ -3.88, 14.48 ]
Subtotal (95% CI) 19 20 100.0 % 5.30 [ -3.88, 14.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
4 Interest/desire
Michelson 2000 19 12.9 (17.5) 20 10.2 (16.5) 100.0 % 2.70 [ -7.99, 13.39 ]
Subtotal (95% CI) 19 20 100.0 % 2.70 [ -7.99, 13.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
5 Lubrication
Michelson 2000 19 13.6 (19.1) 20 3.7 (23.9) 100.0 % 9.90 [ -3.65, 23.45 ]
Subtotal (95% CI) 19 20 100.0 % 9.90 [ -3.65, 23.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.43 (P = 0.15)
6 Orgasm
Michelson 2000 19 7.8 (21.5) 20 14.1 (22.1) 100.0 % -6.30 [ -19.98, 7.38 ]
Subtotal (95% CI) 19 20 100.0 % -6.30 [ -19.98, 7.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
7 Pleasure
Michelson 2000 19 6.5 (17.2) 20 9.7 (21.9) 100.0 % -3.20 [ -15.53, 9.13 ]
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(. . . Continued)
Study or subgroup Buspirone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 19 20 100.0 % -3.20 [ -15.53, 9.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
8 Discomfort
Michelson 2000 19 7.6 (14.8) 20 0.6 (17.5) 100.0 % 7.00 [ -3.15, 17.15 ]
Subtotal (95% CI) 19 20 100.0 % 7.00 [ -3.15, 17.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
-20 -10 0 10 20
Favours placebo Favours buspirone
Analysis 8.2. Comparison 8 Buspirone vs placebo, Outcome 2 Dropouts.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 8 Buspirone vs placebo
Outcome: 2 Dropouts
Study or subgroup Buspirone Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Michelson 2000 2/21 1/21 2.00 [ 0.20, 20.41 ]
0.01 0.1 1 10 100
Favours buspirone Favours placebo
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Analysis 9.1. Comparison 9 Bethanecol vs placebo, Outcome 1 Visual analogue scale of orgasmic function -
best score achieved.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 9 Bethanecol vs placebo
Outcome: 1 Visual analogue scale of orgasmic function - best score achieved
Study or subgroup Bethanecol Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Bernik 2004 10 5.8 (2.7) 10 2.4 (2.8) 3.40 [ 0.99, 5.81 ]
-4 -2 0 2 4
Favours Bethanecol Favours Placebo
Analysis 10.1. Comparison 10 Olanzapine vs placebo, Outcome 1 Change in patient rated assessment of
sexual function.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 10 Olanzapine vs placebo
Outcome: 1 Change in patient rated assessment of sexual function
Study or subgroup Olanzapine Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Overall satisfaction
Michelson 2002 35 -1.5 (1.1) 37 -0.8 (0.9) -0.70 [ -1.17, -0.23 ]
2 Sexual interest
Michelson 2002 35 -0.6 (1.1) 37 -0.7 (1) 0.10 [ -0.39, 0.59 ]
3 Psychological arousal
Michelson 2002 35 -1.1 (1.2) 37 -0.8 (1.2) -0.30 [ -0.85, 0.25 ]
4 Lubrication
Michelson 2002 35 -0.9 (1.2) 37 -0.5 (1.1) -0.40 [ -0.93, 0.13 ]
5 Orgasm
Michelson 2002 35 -1.1 (1.4) 37 -0.7 (1.1) -0.40 [ -0.98, 0.18 ]
-1 -0.5 0 0.5 1
Favours olanzapine Favours placebo
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Analysis 10.2. Comparison 10 Olanzapine vs placebo, Outcome 2 Change in diary ratings (visual analogue
scales).
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 10 Olanzapine vs placebo
Outcome: 2 Change in diary ratings (visual analogue scales)
Study or subgroup Olanzapine Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Overall sexual function
Michelson 2002 35 6.1 (11.3) 37 5.2 (10.1) 0.90 [ -4.06, 5.86 ]
2 Mood
Michelson 2002 35 0.3 (1.1) 37 0.2 (1.1) 0.10 [ -0.41, 0.61 ]
3 Energy
Michelson 2002 35 0 (1.6) 37 0.3 (1.3) -0.30 [ -0.98, 0.38 ]
4 Sexual interest
Michelson 2002 35 0.3 (1.8) 37 0.4 (1.3) -0.10 [ -0.83, 0.63 ]
5 Psychological arousal
Michelson 2002 35 0.8 (2.2) 37 0.9 (2.5) -0.10 [ -1.19, 0.99 ]
6 Physical arousal
Michelson 2002 35 1.4 (2.6) 37 0.8 (2.1) 0.60 [ -0.50, 1.70 ]
7 Orgasm
Michelson 2002 35 1.6 (2.3) 37 1.2 (2) 0.40 [ -0.60, 1.40 ]
8 Pleasure/enjoyment
Michelson 2002 35 1.3 (2.6) 37 1 (2.2) 0.30 [ -0.82, 1.42 ]
9 Discomfort
Michelson 2002 35 0.5 (2.2) 37 0.7 (2) -0.20 [ -1.17, 0.77 ]
-2 -1 0 1 2
Favours placebo Favours olanzapine
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Analysis 10.3. Comparison 10 Olanzapine vs placebo, Outcome 3 Dropouts due to adverse effects.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 10 Olanzapine vs placebo
Outcome: 3 Dropouts due to adverse effects
Study or subgroup Olanzapine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Michelson 2002 7/38 2/39 3.59 [ 0.80, 16.21 ]
0.1 0.2 0.5 1 2 5 10
Favours olanzapine Favours placebo
Analysis 11.1. Comparison 11 Mirtazapine vs placebo, Outcome 1 Change in patient rated assessment of
sexual function.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 11 Mirtazapine vs placebo
Outcome: 1 Change in patient rated assessment of sexual function
Study or subgroup Mirtazapine Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Overall satisfaction
Michelson 2002 35 -0.7 (0.8) 37 -0.8 (0.9) 0.10 [ -0.29, 0.49 ]
2 Sexual interest
Michelson 2002 35 -0.5 (0.8) 37 -0.7 (1) 0.20 [ -0.22, 0.62 ]
3 Psychological arousal
Michelson 2002 35 -0.6 (0.9) 37 -0.8 (1.2) 0.20 [ -0.29, 0.69 ]
4 Lubrication
Michelson 2002 35 -0.7 (1.3) 37 -0.5 (1.1) -0.20 [ -0.76, 0.36 ]
5 Orgasm
Michelson 2002 35 -0.5 (1.1) 37 -0.7 (1.1) 0.20 [ -0.31, 0.71 ]
-0.5 -0.25 0 0.25 0.5
Favours olanzapine Favours placebo
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Analysis 11.2. Comparison 11 Mirtazapine vs placebo, Outcome 2 Change in diary ratings (visual analogue
scales).
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 11 Mirtazapine vs placebo
Outcome: 2 Change in diary ratings (visual analogue scales)
Study or subgroup Mirtazapine Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Overall sexual function
Michelson 2002 35 3.9 (9) 37 5.2 (10.1) -1.30 [ -5.71, 3.11 ]
2 Mood
Michelson 2002 35 -0.2 (1.2) 37 0.2 (1.1) -0.40 [ -0.93, 0.13 ]
3 Energy
Michelson 2002 35 -0.4 (1.6) 37 0.3 (1.3) -0.70 [ -1.38, -0.02 ]
4 Sexual interest
Michelson 2002 35 0.2 (1.3) 37 0.4 (1.3) -0.20 [ -0.80, 0.40 ]
5 Psychological arousal
Michelson 2002 35 0.5 (2.3) 37 0.9 (2.5) -0.40 [ -1.51, 0.71 ]
6 Physical arousal
Michelson 2002 35 0.9 (2.3) 37 0.8 (2.1) 0.10 [ -0.92, 1.12 ]
7 Orgasm
Michelson 2002 35 0.5 (2.1) 37 1.2 (2) -0.70 [ -1.65, 0.25 ]
8 Pleasure/enjoyment
Michelson 2002 35 0.7 (1.9) 37 1 (2.2) -0.30 [ -1.25, 0.65 ]
9 Discomfort
Michelson 2002 35 1.1 (2.1) 37 0.7 (2) 0.40 [ -0.55, 1.35 ]
-2 -1 0 1 2
Favours olanzapine Favours placebo
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Analysis 11.3. Comparison 11 Mirtazapine vs placebo, Outcome 3 Endpoint modified Kinsey Structured
Interview.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 11 Mirtazapine vs placebo
Outcome: 3 Endpoint modified Kinsey Structured Interview
Study or subgroup Mirtazapine Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Sexual satisfaction
Michelson 2002 36 3.2 (0.9) 39 2.6 (0.9) 100.0 % 0.60 [ 0.19, 1.01 ]
Total (95% CI) 36 39 100.0 % 0.60 [ 0.19, 1.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.88 (P = 0.0039)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours mirtazapine Favours placebo
Analysis 11.4. Comparison 11 Mirtazapine vs placebo, Outcome 4 Dropouts.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 11 Mirtazapine vs placebo
Outcome: 4 Dropouts
Study or subgroup Mirtazapine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Attributed to adverse effects
Michelson 2000 12/36 2/39 6.50 [ 1.56, 27.07 ]
0.1 0.2 0.5 1 2 5 10
Favours mirtazepine Favours placebo
118Strategies for managing sexual dysfunction induced by antidepressant medication (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 12.1. Comparison 12 Yohimbine vs placebo, Outcome 1 Change in patient rated assessment of
sexual function.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 12 Yohimbine vs placebo
Outcome: 1 Change in patient rated assessment of sexual function
Study or subgroup Yohimbine Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Overall satisfaction
Michelson 2002 35 -1.1 (1.2) 37 -0.8 (0.9) -0.30 [ -0.79, 0.19 ]
2 Sexual interest
Michelson 2002 35 -0.8 (1) 37 -0.7 (1) -0.10 [ -0.56, 0.36 ]
3 Psychological arousal
Michelson 2002 35 -1.1 (1.1) 37 -0.8 (1.2) -0.30 [ -0.83, 0.23 ]
4 Lubrication
Michelson 2002 35 -0.8 (1.2) 37 -0.5 (1.1) -0.30 [ -0.83, 0.23 ]
5 Orgasm
Michelson 2002 35 -0.9 (1.2) 37 -0.7 (1.1) -0.20 [ -0.73, 0.33 ]
-1 -0.5 0 0.5 1
Favours yohimbine Favours placebo
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Analysis 12.2. Comparison 12 Yohimbine vs placebo, Outcome 2 Change in diary ratings (visual analogue
scales).
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 12 Yohimbine vs placebo
Outcome: 2 Change in diary ratings (visual analogue scales)
Study or subgroup Yohimbine Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Overall sexual function
Michelson 2002 35 6.4 (9.1) 37 5.2 (10.1) 1.20 [ -3.24, 5.64 ]
2 Mood
Michelson 2002 35 0.3 (1.1) 37 0.2 (1.1) 0.10 [ -0.41, 0.61 ]
3 Energy
Michelson 2002 35 0.4 (1.1) 37 0.3 (1.3) 0.10 [ -0.46, 0.66 ]
4 Sexual interest
Michelson 2002 35 1 (1.8) 37 0.4 (1.3) 0.60 [ -0.13, 1.33 ]
5 Psychological arousal
Michelson 2002 35 1 (2) 37 0.9 (2.5) 0.10 [ -0.94, 1.14 ]
6 Physical arousal
Michelson 2002 35 1.7 (2) 37 0.8 (2.1) 0.90 [ -0.05, 1.85 ]
7 Orgasm
Michelson 2002 35 1.1 (1.9) 37 1.2 (2) -0.10 [ -1.00, 0.80 ]
8 Pleasure/enjoyment
Michelson 2002 35 1.2 (2.1) 37 1 (2.2) 0.20 [ -0.79, 1.19 ]
9 Discomfort
Michelson 2002 35 0.3 (2.3) 37 0.7 (2) -0.40 [ -1.40, 0.60 ]
-2 -1 0 1 2
Favours olanzapine Favours placebo
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Analysis 12.3. Comparison 12 Yohimbine vs placebo, Outcome 3 Dropouts.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 12 Yohimbine vs placebo
Outcome: 3 Dropouts
Study or subgroup Yohimbine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Attributed to adverse effects
Michelson 2002 4/35 2/39 2.23 [ 0.43, 11.43 ]
0.1 0.2 0.5 1 2 5 10
Favours yohimbine Favours placebo
Analysis 13.1. Comparison 13 Amantadine vs placebo, Outcome 1 Change in patient-rated visual analogue
scales.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 13 Amantadine vs placebo
Outcome: 1 Change in patient-rated visual analogue scales
Study or subgroup Amantadine Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Overall function (total of interest, lubrication, orgasm, pleasure)
Michelson 2000 18 50.7 (64.3) 20 37.7 (67.8) 100.0 % 13.00 [ -29.02, 55.02 ]
Subtotal (95% CI) 18 20 100.0 % 13.00 [ -29.02, 55.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
2 Mood
Michelson 2000 18 8.7 (10.4) 20 0.6 (11.2) 100.0 % 8.10 [ 1.23, 14.97 ]
Subtotal (95% CI) 18 20 100.0 % 8.10 [ 1.23, 14.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.31 (P = 0.021)
3 Energy
-20 -10 0 10 20
Favours placebo Favours amantadine
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(. . . Continued)
Study or subgroup Amantadine Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Michelson 2000 18 9.5 (8.8) 20 -3.2 (14.1) 100.0 % 12.70 [ 5.30, 20.10 ]
Subtotal (95% CI) 18 20 100.0 % 12.70 [ 5.30, 20.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.37 (P = 0.00076)
4 Interest/desire
Michelson 2000 18 11.1 (11.1) 20 10.2 (16.5) 100.0 % 0.90 [ -7.96, 9.76 ]
Subtotal (95% CI) 18 20 100.0 % 0.90 [ -7.96, 9.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
5 Lubrication
Michelson 2000 18 11.6 (18.9) 20 3.7 (23.9) 100.0 % 7.90 [ -5.74, 21.54 ]
Subtotal (95% CI) 18 20 100.0 % 7.90 [ -5.74, 21.54 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.26)
6 Orgasm
Michelson 2000 18 16.6 (23.1) 20 14.1 (22.1) 100.0 % 2.50 [ -11.91, 16.91 ]
Subtotal (95% CI) 18 20 100.0 % 2.50 [ -11.91, 16.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.73)
7 Pleasure
Michelson 2000 18 11.4 (18.9) 20 9.7 (21.9) 100.0 % 1.70 [ -11.28, 14.68 ]
Subtotal (95% CI) 18 20 100.0 % 1.70 [ -11.28, 14.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.80)
8 Discomfort
Michelson 2000 18 1.9 (21.5) 20 0.6 (17.5) 100.0 % 1.30 [ -11.25, 13.85 ]
Subtotal (95% CI) 18 20 100.0 % 1.30 [ -11.25, 13.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
-20 -10 0 10 20
Favours placebo Favours amantadine
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Analysis 13.2. Comparison 13 Amantadine vs placebo, Outcome 2 Dropouts.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 13 Amantadine vs placebo
Outcome: 2 Dropouts
Study or subgroup amantadine placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Michelson 2000 1/19 1/21 1.11 [ 0.07, 16.47 ]
0.1 0.2 0.5 1 2 5 10
Favours amantadine Favours placebo
Analysis 14.1. Comparison 14 ephedrine vs placebo, Outcome 1 Endpoint Brief Index of Sexual Functioning
for Women (BISF-W).
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 14 ephedrine vs placebo
Outcome: 1 Endpoint Brief Index of Sexual Functioning for Women (BISF-W)
Study or subgroup Ephedrine Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Sexual desire
Meston 2004 19 1.79 (0.78) 19 1.95 (0.78) -0.16 [ -0.66, 0.34 ]
2 Sexual arousability
Meston 2004 19 1.21 (0.78) 19 1.37 (0.78) -0.16 [ -0.66, 0.34 ]
3 Lack of vaginal lubrication
Meston 2004 19 1.36 (1.26) 19 1.44 (1.48) -0.08 [ -0.95, 0.79 ]
4 Orgasm ability
Meston 2004 19 1.29 (0.83) 19 1.39 (0.61) -0.10 [ -0.56, 0.36 ]
5 Orgasm intensity/pleasure
Meston 2004 19 1.25 (0.83) 19 1.39 (0.74) -0.14 [ -0.64, 0.36 ]
6 Sexual dissatisfaction
Meston 2004 19 1.91 (0.83) 19 1.86 (0.87) 0.05 [ -0.49, 0.59 ]
-1 -0.5 0 0.5 1
Favours placebo Favours ephedrine
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Analysis 15.1. Comparison 15 Maca root: high vs low dose, Outcome 1 Endpoint Arizona Sexual
Experiences Scale (ASEX) score.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 15 Maca root: high vs low dose
Outcome: 1 Endpoint Arizona Sexual Experiences Scale (ASEX) score
Study or subgroup High dose maca Low dose maca root
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Total score
Dording 2008 9 16.9 (6.2) 7 17.7 (5.4) -0.80 [ -6.49, 4.89 ]
2 Question 1: Sexual desire
Dording 2008 9 3.7 (1.7) 7 3.4 (1.7) 0.30 [ -1.38, 1.98 ]
-4 -2 0 2 4
Favours High dose maca Favours Low dose maca root
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Analysis 15.2. Comparison 15 Maca root: high vs low dose, Outcome 2 Endpoint MGH-SFQ.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 15 Maca root: high vs low dose
Outcome: 2 Endpoint MGH-SFQ
Study or subgroup High dose maca Low dose maca root
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Total score
Dording 2008 9 17 (5.7) 7 19 (5.8) -2.00 [ -7.69, 3.69 ]
2 Item a: Sexual desire
Dording 2008 9 3.3 (1.3) 7 3.4 (1.7) -0.10 [ -1.62, 1.42 ]
-4 -2 0 2 4
Favours High dose maca Favours Low dose maca root
Analysis 15.3. Comparison 15 Maca root: high vs low dose, Outcome 3 Dropouts.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 15 Maca root: high vs low dose
Outcome: 3 Dropouts
Study or subgroup High dose maca Low dose maca root Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dording 2008 6/10 4/10 100.0 % 1.50 [ 0.60, 3.74 ]
Total (95% CI) 10 10 100.0 % 1.50 [ 0.60, 3.74 ]
Total events: 6 (High dose maca), 4 (Low dose maca root)
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.38)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours High dose maca Favours Low dose maca root
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Analysis 15.4. Comparison 15 Maca root: high vs low dose, Outcome 4 Endpoint ratings of psychiatric
symptoms.
Review: Strategies for managing sexual dysfunction induced by antidepressant medication
Comparison: 15 Maca root: high vs low dose
Outcome: 4 Endpoint ratings of psychiatric symptoms
Study or subgroup High dose maca Low dose maca root
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Hamilton Depression Rating Scale
Dording 2008 9 3.2 (1.9) 7 5.7 (7.2) 100.0 % -2.50 [ -7.98, 2.98 ]
Subtotal (95% CI) 9 7 100.0 % -2.50 [ -7.98, 2.98 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.37)
2 Hamilton Anxiety Rating Scale
Dording 2008 9 2.6 (1.4) 7 3 (3.5) 100.0 % -0.40 [ -3.15, 2.35 ]
Subtotal (95% CI) 9 7 100.0 % -0.40 [ -3.15, 2.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.78)
Test for subgroup differences: Chi2 = 0.45, df = 1 (P = 0.50), I2 =0.0%
-10 -5 0 5 10
Favours High dose maca Favours Low dose maca
A P P E N D I C E S
Appendix 1. CCDANCTR-References Register
Sexual dysfunction
1. Free-text: ((sex* and (disorder* or disturb* or dysfunction* or function or “side effect*” or “adverse effect*” or
“adverse event*”)) or (sex* and (desire or thoughts or excitement)) or arous* or ejaculat* or erectile
or erection* or impoten* or orgasm* or anorgasm* or hyperorgasm* or libido or hyposexual* or
psychosexual)
Antidepressants
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(Continued)
2. Free-text: (antidepress* or anti-depress* or “anti depress*” or MAOI* or “monoamine oxidase inhibit*” or (
(serotonin or norepinephrine or noradrenaline or neurotransmitt* or dopamine*) and (uptake or
reuptake or re-uptake)) or SSRI* or SNRI* or TCA* or tricyclic* or tetracyclic* or heterocyclic* or
pharmacotherap*)
3. Free-text: (Agomelatine or Alnespirone or Amoxapine or Amfebutamone or Amiflamine or Aminep-
tine or Amitriptylin* or Amitriptylinoxide or Amoxapine or Aripiprazole or Atomoxetine or
Tomoxetine or Befloxatone or Benactyzine or Binospirone or Brofaromine or Bupropion or
Butriptylin* or Cianopramine or Cilobamine or Cimoxatone or Citalopram or (Chlorimipramin*
orClomipramin* orChlomipramin* orClorimipramine) orClorgyline orClovoxamine or (CX157
or Tyrima) or Dapoxetine or Deanol or Dibenzepin or Demexiptilin* or Deprenyl or Desipramine
or Desvenlafaxine or Dibenzepin or Dimetacrin* or (Dosulepin or Dothiepin) or Doxepin or Du-
loxetine or DVS-233 or Enilospirone or Eptapirone or Escitalopram or Etoperidone or Femoxetine
or Fluotracen or Fluoxetine or Furazolidone or Fluvoxamine or Harmaline or Harmine or Hyper-
forin or (Hypericum or (John* and Wort) or “WS 5570” or “WS 5572” or “LI 160” or LoHyp-
57) or Idazoxan or Imipramin* or Iprindole or Iproniazid* or Ipsapirone or Imipraminoxide or
Isocarboxazid* or Lesopitron or Levomilnacipran or Lithium or Lofepramin* or (“Lu AA21004”
or Vortioxetine) or “Lu AA24530” or LY2216684 or Maprotiline or Medifoxamine or Melitracen
or Metapramine or Methylphenidate or Mianserin or Milnacipran or Minaprine or Mirtazapine
or Moclobemide or Nefazodone or Nialamide or Nitroxazepine or Nomifensine or Nortriptyline
or Noxiptilin* or Opipramol or Paroxetine or Phenelzine or Pipofezin* or Piribedil or Pirlin-
dole or Pivagabine or Pizotyline or Propizepine or (Protriptylin* or Pertofrane) or Quinupramine
or Quipazine or Reboxetine or Ritanserin or Rolipram or Scopolamine or Selegiline or Sertra-
line or (Setiptiline or Teciptiline) or Tandospirone or Tetrindole or Thiazesim or Thozalinone or
Tianeptin* or Toloxatone or Tranylcypromine or Trazodone or Trimipramine or 5-Hydroxytrypto-
phan or 5-HT or Tryptophan or Hydroxytryptophan or Venlafaxine or Viloxazine or Vilazodone
or Viqualine or Zalospirone or Zimeldine)
4. Free-text: (Alaproclate or Caroxazone or Diclofensine or Fenfluramine or Fluparoxan or Norfenfluramine or
Pheniprazine)
5. Keywords: (depress* and “drug therap*”)
6. or/2-5
7. (1 and 6)
Appendix 2. CENTRAL, CINAHL, EMBASE, MEDLINE, PsycINFO: original search strategy
The Cochrane Central Register of Controlled Trials (CENTRAL Issue 2, 2004) was searched using the following search terms:
#1(sexual* and dysfunction*)
#2 psychosexual
#3 orgasm*
#4 impoten*
#5 erecti*
#6 priapism
#7 libido
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#8 frigid*
#9 vaginism*
#10 lubricat*
#11 dyspareun*
#12 anorgasm*
#13 hyperorgasm*
#14 (hypoactive and (sexual and desire)
#15 (sexual* and unresponsive*)
#16 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 )
#17 sr-depressn
#18 (#16 not #17).
CINAHL (1982-March Week 4 2004) was searched with the following terms:
1 exp Dyspareunia/
2 exp Penile erection/
3 exp orgasm/
4 priap$.mp. [mp=title, cinahl subject heading, abstract,
instrumentation]
5 lubricat$.mp. [mp=title, cinahl subject heading, abstract,
instrumentation]
6 (sexual adj dysfunct$).mp. [mp=title, cinahl subject
heading, abstract, instrumentation]
7 (sexual adj problem$).mp. [mp=title, cinahl subject
heading, abstract, instrumentation]
8 (sexual adj arousal).mp. [mp=title, cinahl subject heading,
abstract, instrumentation]
9 (sexual adj satisf$).mp. [mp=title, cinahl subject heading,
abstract, instrumentation]
10 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9
11 exp Sexual dysfunction/
12 exp Impotence/
13 11 or 12
14 10 not 13
EMBASE (1980-2004 Week 13) was searched with the following terms:
1 exp controlled study/
2 exp clinical trial/
3 exp major clinical study/
4 exp randomized controlled trial/
5 exp double blind procedure/
6 exp clinical article/
7 random$.mp.
8 trial$.mp.
9 study.mp.
10 studi$.mp.
11 compar$.mp.
12 control$.mp.
13 follow$.mp.
14 placebo$.mp.
15 ((dingl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or
mask$ or dummy)).mp. [mp=title, abstract, heading word,
trade name, manufacturer name]
16 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
or 13 or 14 or 15
17 (animal or non-human).mp.
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18 human.mp.
19 17 not 18
20 16 not 19
21 exp Dyspareunia/
22 exp Priapism/
23 exp Libido/
24 exp orgasm/
25 exp penis erection/
26 lubricat$.mp. [mp=title, abstract, heading word, trade
name, manufacturer name]
27 (sexual adj dysfunct$).mp. [mp=title, abstract, heading
word, trade name, manufacturer name]
28 (sexual adj problem$).mp. [mp=title, abstract, heading
word, trade name, manufacturer name]
29 (sexual adj arousal).mp. [mp=title, abstract, heading word,
trade name, manufacturer name]
30 (sexual adj satisf$).mp. [mp=title, abstract, heading word,
trade name, manufacturer name]
31 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30
32 exp Sexual dysfunction/
33 exp Impotence/
34 32 or 33
35 31 not 34
36 20 and 35
Medline (1966-June Week 4 2004) was searched with the following terms:
1 exp Dyspareunia/
2 exp Priapism/
3 libido.mp. [mp=title, abstract, registry number word, mesh
subject heading]
4 orgasm$.mp. [mp=title, abstract, registry number word, mesh
subject heading]
5 erecti$.mp. [mp=title, abstract, registry number word, mesh
subject heading]
6 lubricat$.mp. [mp=title, abstract, registry number word,
mesh subject heading]
7 (sexual adj dysfunct$).mp. [mp=title, abstract, registry
number word, mesh subject heading]
8 (sexual adj problem$).mp. [mp=title, abstract, registry
number word, mesh subject heading]
9 (sexual adj arousal).mp. [mp=title, abstract, registry
number word, mesh subject heading]
10 (sexual adj satisf$).mp. [mp=title, abstract, registry
number word, mesh subject heading]
11 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10
12 exp impotence/ or exp sexual dysfunctions, psychological/
13 11 not 10
14 11 not 12
15 exp Sex disorders/
16 11 or 15
17 16 not 12
18 (“randomized controlled trial” or “controlled clinical
trial”).pt.
19 17 and 18
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PsycINFO (1984- March Week 4 2004) was searched with the following terms:
1 exp dyspareunia/
2 exp libido/
3 exp orgasm/
4 exp “erection (penis)”/
5 lubricat$.mp. [mp=title, abstract, heading word, table of
contents, key phrase identifiers]
6 (sexual adj dysfunct$).mp. [mp=title, abstract, heading
word, table of contents, key phrase identifiers]
7 (sexual adj problem$).mp. [mp=title, abstract, heading
word, table of contents, key phrase identifiers]
8 (sexual adj arousal).mp. [mp=title, abstract, heading word,
table of contents, key phrase identifiers]
9 (sexual adj satisf$).mp. [mp=title, abstract, heading word,
table of contents, key phrase identifiers]
10 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9
11 exp impotence/
12 10 not 11
WH A T ’ S N E W
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Date Event Description
1 April 2013 New search has been performed Methodology and search updated
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